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ABSTRACT 
 
Shape memory polymers (SMPs) are a class of materials that can be programmed 
into a secondary, metastable geometry and subsequently stimulated to return to their 
original geometry. These biocompatible materials enable the delivery and subsequent 
expansion of multiple catheter-based medical devices, including low density foams for 
embolic applications. In this work, cold plasma surface modifications and bulk 
compositional changes were used to address three design limitations of previous SMP 
systems: controlled foam expansion, controlled foam membrane removal, and inherent 
x-ray visibility. 
SMP parameters including glass transition temperature, foam pore size, 
expansion rate in water, and x-ray contrast can be modified by altering the SMP 
composition or by using particulate additives to form an SMP composite. However, 
aggressive changes in bulk material chemistry can also affect properties associated with 
the surface, such as biocompatibility or hydrophobicity.  To address the current 
limitations of SMP devices, this dissertation investigates the use of cold gas plasma 
techniques as an additional tool to alter surface material properties independent of bulk 
material composition. 
The material modifications imparted by plasma processes or changes in 
composition were first analyzed on simple film and bulk substrates using techniques 
such as ellipsometry, x-ray photoelectron spectroscopy, Fourier transform infrared 
spectroscopy, differential scanning calorimetry, dynamic mechanical analysis, uniaxial 
iii 
tensile testing, and goniometry. After material characterization, each process was applied 
to a specific medical device application and characterized based on device performance 
criteria. Device-specific characteristics, including cell-material interactions, x-ray 
visibility, fluid permeability, and expansion kinetics, were conducted on device 
prototypes using confocal microscopy, fluoroscopic imaging, flow system analysis, and 
isothermal expansion imaging, respectively. 
Cold plasma film deposition using hydrocarbon gases was proven to influence 
SMP foam expansion kinetics by modulating the rate of moisture plasticization. 
Additionally, oxygen and tetrafluoromethane cold plasmas preferentially removed foam 
membranes to increase the interconnected porosity and fluid permeability of embolic 
SMP scaffolds with minimal impacts on material toughness. Finally, chemically 
 incorporating triiodobenzene containing monomers not only provided x-ray 
visibility, but also significantly improved tensile toughness. 
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1 
CHAPTER I  
INTRODUCTION* 
1.1 Shape memory polymers 
Shape memory polymers (SMPs) are a class of materials that can be stimulated to 
actuate from a programmed, secondary metastable geometry to a primary geometry. This 
entropy driven process can be stimulated in a variety of ways, but this work focuses on 
thermally actuated SMPs, which actuate over a characteristic transition temperature.[5] 
This shape memory effect has been utilized to create devices with intricate geometries 
that are compressible to diameters small enough for delivery into the body via 
microcatheter. Once delivered to the target anatomy, the devices can be actuated to 
restore their primary shape and perform a therapeutic function. This approach has been 
previously implemented for the design of devices such as stents, thrombectomy devices, 
and laser stimulated micro actuators.[6-8] 
SMPs consist of net points, which are a part of the stable polymer network, and 
reversible switching segments.[9, 10] Net points are responsible for the original shape 
while the switching segments provide the secondary shape and allow for shape change to 
occur. A thermally actuated SMP can be programmed, via external stress, into a 
secondary shape after being heated above the transition temperature of the switching 
segments. The new shape can be set by cooling at a constant load. The new shape is at a 
higher energy state because the new orientation of the polymer chains decreases the 
*Parts of this chapter were reprinted from “Porous Shape Memory Polymers: Design
and Applications,” by Sayyeda M. Hasan, Landon D. Nash, Duncan J. Maitland,
Journal of Polymer Science Part B: Polymer Physics 2016. Copyright (2016) John
Wiley and Sons.
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entropy of the system. However, the rigidity of the polymer chains below the transition 
temperature prevents the polymer from relaxing to the lower energy primary shape. 
When heated above the transition temperature, the programmed SMP returns to its 
original shape due to entropic recovery of the net points.[11, 12] In addition to ambient 
changes in temperature, this shape change can be triggered by different stimuli such as 
light, magnetic field, pH, solvent, and electricity and is dependent on the polymer type 
and incorporation of additives such as nanoparticles.[13]. 
1.1.1 Shape memory polymer medical devices 
The biomedical device lab leverages the shape memory effect to create 
minimally invasive SMP medical devices.[14] These devices include shape memory 
polymer stents, septal occludes, thrombectomy devices, and embolic foams for 
peripheral vessel and aneurysm occlusion.[1, 4, 15-19]  
Work by Nash et al. proposed a shape memory polymer microactuator for 
releasing microcatheter-based medical devices, such as SMP embolic foams.[20] This 
release device consists of a nichrome wire coil that resistively heats a shape set SMP 
tube, triggering it to radially expand and axially retract from the heating coil. The 
nichrome coil and crimped polymer tube are configured around a T type thermocouple to 
provide the user with temperature feedback and prevent the device from overheating 
within the patient. Figure 1.1 summarizes an in-vitro prototype deployment. 
Although many SMP devices show promise for improving clinical outcomes for 
medical devices, the device designs and constituent materials still require improvement 
to create commercially viable devices that can translate from the research environment 
 3 
 
to use in real patients. This dissertation focuses on solving technical hurdles for SMP 
devices to help facilitate clinical translation of SMP medical technologies. 
 
 
Figure 1.1: Top: Sequenced images depicting micro-release device actuation. 
Asterisks identify the expanded portion of the SMP tube. Bottom: Measured device 
temperature at each stage of release. 
 
1.2 Porous shape memory polymers 
Porous shape memory polymers have become particularly popular in the medical 
industry. Traditionally, porous polymers had applications as insulators and ion exchange 
resins.[21] However, these materials have also found use in the medical community as 
tissue engineering scaffolds for bone, drug delivery vehicles, and optical sensors.[21] 
Porous SMPs have a unique advantage as biomaterials because they can be implanted 
via minimally invasive procedures and undergo geometric changes after 
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implantation.[22] For tissue engineering applications, porous SMPs can be designed to 
serve as self-fitting scaffolds for tissue growth. Some stimulus-responsive hydrogels are 
also considered to be SMPs; however, this review will focus on porous SMPs that 
contain pores on the micrometer or larger scale. 
1.2.1 Particulate leaching 
Particle leaching is a fabrication technique that provides porous scaffolds with 
well-interconnected cells.[23, 24] This process consists of leaching solid particles out of 
a polymer system.[23, 25] A polymer solution is synthesized at varying solvent 
concentrations (5-20%).[26] Salt particles with a fixed diameter are mixed into the 
polymer/solvent solution to ensure uniform distribution.[27] The solvent is then removed 
via air-drying, vacuum-drying, or freeze-drying, leaving behind the salt particles 
embedded into the polymer matrix.[28] The polymer/solid composite is further 
immersed in water to dissolve the salt particles, leaving behind a porous, interconnected 
polymer scaffold.[27] 
Scaffold porosity and cell size are dependent on the particle concentration and 
diameter, respectively.[25, 29] Insufficient particle concentration results in isolated 
pores that are surrounded by a thick layer of polymer. However, high particle loading 
causes voids, due to close poragen packing, which ultimately decreases mechanical 
properties. Hariraksapitak et al. reported changes in scaffold porosity directly related to 
particle concentration.[26] By increasing the particle concentration from 25x to 40x, 
larger voids were generated, which caused a significant decrease in mechanical 
properties. However, using particles ranging between 200–400 μm maintained uniform 
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pore size within the scaffold.[26] Most particle leaching techniques utilize salts; 
however, other particles such as sugar, ammonium chloride, sucrose, starch, paraffin, 
and gelatin particles have also been reported.[24, 25, 27] 
Advantages of particle leaching include the ease of fabrication, since no 
specialized equipment is required for scaffold synthesis, uniform cell sizes, and 
interconnected pores. Difficulty associated with selecting particle type and size is a 
disadvantage because maintaining high porosity and adequate mechanical strength is a 
challenge. Lastly, unlike gas foaming, particle leaching has a risk of solvent toxicity on 
cells infiltrating the scaffold.[30] 
1.2.2 PolyHIPEs 
Porous scaffolds can be constructed from polymerized high internal phase 
emulsions (PolyHIPEs). HIPEs are typically defined as paste-like emulsions consisting 
of over 74% “internal” phase distributed within a continuous “external” phase.[31, 32] 
These scaffolds are particularly useful for biomedical applications due to their inherent 
potential for interconnected porosity. However, these emulsions are typically stabilized 
during polymerization by large amounts of surfactants. The impact of residual surfactant 
on material properties and the cost associated with the use and removal of these 
surfactants have motivated the use of alternative interface stabilization methods. 
Surfactant-free Pickering HIPES are stabilized at the oil-water interface by solid 
amphiphilic particles that migrate and self-assemble at the boundary layer.[33] These 
emulsions approach monodisperse void sizes, and they resist coalescence due to higher 
nanoparticle desorption energies when compared to traditional surfactants.[34-36] 
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Additional information on PolyHIPEs and Pickering HIPEs can be found in 
comprehensive reviews by Silverstein.[37, 38] 
Specific to shape memory scaffolds, acrylate and methacrylate Pickering HIPES 
with shape memory capacities were successfully fabricated using silane functionalized 
nanoparticulate silica stabilizers that doubled as crosslinking centers to enable shape 
memory via side chain crystallization.[39] Gel content for each composition was above 
90%, demonstrating effective nanoparticulate crosslinking. These constructs also 
demonstrated modest pore interconnectivity, recovery ratios of 1, and melt transitions 
ranging from 29 to 48 °C. 
1.2.3 Gas blown polyurethane foams 
 Although gas blowing is traditionally used to create commercial polymer foams 
for thermal and mechanical insulation, the use of this fabrication technique has 
significantly increased in the medical industry.[21, 25] 
Regardless of the desired application or foaming process being used, cell 
nucleation and growth of bubbles are important for the development of pores.[40, 41] 
Bubbles can be generated using three different methods: chemical, physical, and 
biological blowing. Chemical blowing agents generate gas due to a chemical reaction 
while physical blowing agents cause bubble formation as a result of mechanical action or 
phase transitions.[40] Biological agents are usually bacterial species that generate gas as 
a result of their metabolic functions.[40] Carbon dioxide (CO2) and other volatile 
solvents are typical blowing agents due to their low critical point, non-flammability, and 
non-toxicity.[41, 42] 
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Gas foaming can be divided into two classes. The first class occurs when a liquid 
phase turns to vapor as a result of pressure drop or temperature rise.[40] Singhal et al. 
developed SMP foams that utilized gas blowing to achieve solid polyurethane foams. 
This polymer system was chemically crosslinked during foaming to maintain the pore 
morphology and prevent bubble coalescence.[3] Water was the chemical blowing agent 
for synthesis. During foam blowing, water reacted with the isocyanate monomers to 
generate carbon dioxide. The released gas provided cell nucleation and yielded a porous 
material with good interconnectivity. Pore structure and interconnectivity were tuned by 
controlling the type of foaming agent and its concentration in the polymer-gas 
mixture.[42] Reduced scaffold toxicity for in vivo applications is an advantage of gas 
blowing when compared to other fabrication methods.[25] Disadvantages associated 
with gas blowing include difficult control over pore sizes and connectivity.[25] 
In the second class of gas-blown foams, a gas phase separates from a 
supersaturated solution due to changes in pressure and temperature. Inert gasses, such as 
carbon dioxide, can be compressed into supercritical fluids at pressures and temperatures 
above their critical point. These supercritical fluids simultaneously possess fluid 
characteristics, namely density, and gas properties such as compressibility and mass 
diffusion, which collectively enable supercritical fluids to solvate polymer networks. 
[43] Once the supercritical pressure conditions are removed, the dissolved gas expands 
and blows the polymer into a porous structure. The lack of residual solvents, catalysts, 
and surfactants make supercritical fluids attractive for creating porous structures for 
biomedical and tissue engineering applications.[44, 45] Supercritical carbon dioxide has 
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been used to create porous structures from blends of thermoplastic polyurethane and 
polylactic acid. Because the foam formation occurs below the thermal transition, these 
scaffolds have a dynamic, contractible porous structure that is proposed for drug delivery 
systems and wound dressings.[17] 
1.3 Embolic applications for SMP foams 
Low density SMP embolic foams have been proposed as a solution to alleviate 
the numerous drawbacks associated with current therapies for both intracranial and 
peripheral embolization.[3, 17, 46] Low density SMP foams can be compressed to 
fractions of their expanded volume, allowing them to be delivered through a 
microcatheter. As shown in Figure 1.2, a stimulus, such as heat, can restore the 
compressed foam to its original expanded geometry. The volumetric expansion 
capabilities and demonstrated biocompatibility of SMP foams make them a promising 
solution for providing more effective embolization and improved healing. However, 
additional work is needed to achieve facile device delivery and appropriate foam 
actuation profiles for commercial medical applications. 
Previous work with SMP foams has focused on tailoring properties, such as the 
thermo-mechanical behavior or x-ray contrast, using bulk material changes or particulate 
additives, respectively.[47, 48] These approaches have achieved varying degrees of 
success for each application and frequently occur at the expense of other performance 
criteria. This dissertation solves material performance deficiencies using alternative 
techniques (surface or bulk chemistry modifications) in an effort to preserve desirable  
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bulk material properties. Each aim is focused within the scope of a specific device 
application, either peripheral or intracranial aneurysm embolization. 
1.3.1 Aneurysm embolization 
The current gold standard for preventing hemorrhagic stroke involves treating 
intracranial aneurysms with bare platinum coils (BPCs), which are delivered through a 
microcatheter and left within the aneurysm to initiate a clotting response and divert 
blood flow from the aneurysm sac.[49] BPCs have helped to reduce the annual number 
of hemorrhagic stokes in the United States to approximately 103,000, but this treatment 
still has clinical limitations.[50] For instance, volumetric filling densities that are 
considered to be very high by clinical standards (30-35%) may not induce complete 
embolization.[51] Attempts to increase packing density with more coils can lead to over-
packing and eventual aneurysm rupture. Embolizations that are initially effective can 
have recanalization rates as high as 35% and 50% in large and giant aneurysms, 
respectively.[49] Treating large aneurysms (11-20 mm diameter) requires an average of 
159.5 cm of coils to completely occlude the aneurysm, which can cost as much as 
$97,000.[52, 53] This cost is associated with the number and type of implanted coils, as 
well as increased procedure time and complexity. Thus, the cost and efficacy limitations 
 
Figure 1.2: Time-lapsed images depicting the expansion of compressed SMP 
foam when submerged in a heated water bath. Scale is 2.5 mm.[3] 
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of BPCs demand solutions for more efficient volumetric filling of intracranial 
aneurysms.   
Stent-assisted coiling can be used to safely increase packing densities; however, 
this method occurs at the expense of higher procedure cost due to additional coils and a 
stent to bridge the aneurysm neck.[54-56] Despite their effective initial occlusion rates, 
stent-assisted coiling procedures still have recanalization rates as high as 12%.[56] 
Hydrogel-coated coils have been developed to increase volumetric aneurysm filling for 
comparable coil lengths. After implantation, the hydrophilic coating on these coils swells 
with water to effectively increase the coil diameter. Hydrocoils can consistently achieve 
packing densities above 50%, and they often achieve densities 3 times greater than bare 
platinum coils.[52] Despite these demonstrated packing densities, studies have shown no 
clear advantage for preventing aneurysm recurrence by coating platinum coils with 
hydrogels, making the additional cost associated with hydrophilic coatings 
unwarranted.[57, 58] 
Significant advancements in the mechanical design and coating of bare platinum 
embolic coils have given clinicians a broad portfolio of devices to treat a wide variety of 
aneurysm geometries. However, there is still no clear endovascular solution for 
effectively treating all intracranial aneurysms, especially those classified as large or 
giant. There is still a clinical need for a reliable and cost-efficient embolization device 
with negligible recanalization rates.  
Embolic SMP foams are proposed as an effective solution to these current 
clinical limitations. Figure 1.3 summarizes healing outcomes for SMP foams surgically 
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implanted in a porcine vein pouch aneurysm model. This dissertation addresses technical 
hurdles for the translation of microcatheter-delivered neurovascular embolic SMP coils, 
including tailored expansion profiles and improved x-ray visualization.  
 
 
 
 
 
 
Figure 1.3: Pathology summary for SMP foams implanted in a porcine 
aneurysm model. Column A.1 depicts dissected aneurysms both ex vivo and in 
situ at 0-, 30-, and 90-day time points. Each aneurysm was filled with tungsten-
doped embolic SMP foams.[4] Column A.2 shows clotting after initial 
implantation, healing, and complete endothelialization at 0-, 30-, and 90-day 
time points, respectively. Column A.3 is comprised of scanning electron 
microscope (SEM) images of the interface between the foam and vessel wall at 
the three time points. The red blood cells and fibrin within the first image are 
indicative of clotting at zero days. The lack of polymer strut visibility at 30 days 
is indicative of a developing mature endothelial covering. At 90 days, a mature 
endothelial lining obstructs any visibility of polymer struts. SEM images of 
healing at the base apex of the foam make up column A.4. The healing trends at 
each time point are similar to those seen in column A.3. 
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1.3.2 Peripheral embolization 
In addition to aneurysm embolization, clinical needs exist for a variety of 
peripheral embolization applications. For example, better therapeutics are needed for the 
estimated 6 million Americans who suffer from severe symptoms of chronic venous 
insufficiency (CVI).[59] CVI occurs when venous valves are compromised and allow 
backflow in peripheral veins, leading to blood pooling, discomfort, varicose veins, and 
even venous ulcers. The manifestation and recurrence of venous ulcers contribute to the 
majority of costs associated with CVI, accounting for $1 billion in costs annually in the 
US.[60] 
Although there are a multitude of embolization devices with peripheral 
indications, they have general limitations in the venous circulation due to the inherent 
compliance of veins and the presence of valves that may impede proper device 
placement and apposition to the vessel wall. Further, some treatments require 
embolization of large vessels, such as the full length of the great saphenous vein. The 
current standard of care for treating CVI is endovenous ablation (EVA), an ultrasound-
guided therapy that uses a high energy source (e.g. lasers or radiofrequency generators) 
to cause significant damage to the vessel endothelium, leading to fibrous obliteration of 
the lumen. This treatment improves upon previous treatments, such as surgical ligation 
and stripping with recurrence rates as high as 52%; however, EVA is not without 
limitations.[61] For example, technique-dependent variables still make EVA susceptible 
to recanalization, which occurs after 24% of procedures.[62] Further, treatment options 
with EVA are limited because it cannot be used to treat short or highly tortuous 
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vessels.[62, 63] One of the largest drawbacks to the procedure is significant pain 
associated with multiple local anesthesia injections along the length of the vessel. These 
uncomfortable deep tissue injections are implemented to help alleviate long-term pain 
associated with the procedure and to provide an additional fluid volume to act as a heat 
sink during the procedure.[64] 
As an alternative to stiff nitinol mesh occlusion plugs or multiple implanted 
embolic platinum coils, the superior embolization and long-term healing outcomes 
observed for SMP foams have been proposed as a superior solution to enable peripheral 
embolization with a single implanted device.[16, 17] This dissertation proposes 
techniques to alter the morphology and functional performance of gas-blown SMP 
scaffolds to enable this type of device. These material alterations are intended to 
improve device performance in terms of hemodynamics, acute cellular response, and 
noninvasive device visualization. 
1.4 Cold plasma surface modifications 
Cold plasmas, also known as nonequilibrium/nonthermal/low-temperature 
plasmas, are partially ionized reactive gasses.[65] The plasma field is an excited gaseous 
fluid system consisting of free electrons, radicals, ions, and neutral molecules. This 
reactive environment enables a wide variety of surface modifications on substrates 
including metals, ceramics, composites, and even temperature-sensitive polymers.[66] 
Advantages of plasma surface modification include non-line-of-sight 
modification of intricate part geometries (e.g. Foams), flexible process chemistry, room 
temperature processing, and surface sterilization. These processing advantages enable a 
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variety of functional surface changes varying from chemical composition, surface 
roughness, electrical conductivity, optical characteristics, and biological interaction.[67-
69] 
Although plasma modification requires an initial investment in capital 
equipment, the consumable gasses are relatively inexpensive with minimal 
environmental impact compared to solvent-based wet chemistry surface 
modifications.[70] Plasma processes are also compatible with masking techniques 
typically found in the microelectronics industry to enable high fidelity surface 
patterning.[66] 
1.4.1 Industrial plasma applications 
Non-medical applications of plasma surface modifications include deposition of 
diamond-like carbon for low friction coatings, superhydrophobic surfaces for 
microfluidics or antifouling properties, increased surface adhesion of adhesives for 
composite manufacturing, and increased wetting of textiles for improved dye 
absorption.[71-75] Plasma processes have proven to be particularly useful in the 
semiconductor industry for etching microelectronic features in silicon wafers and 
removing polymer resist.[76, 77] These oxidizing plasmas serve as the basis for the 
reticulation plasmas used in chapter 3. Overall, the breadth of industry applications 
highlights the versatility of plasma functionalization for engineered surface solutions.  
1.4.2 Biomedical plasma modification applications 
Plasma processes are particularly useful for modifying biomaterial surfaces that 
interact with their implanted biologic environment.[68] Decoupling surface 
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characteristics from bulk material properties creates the opportunity for improved 
biomedical device performance.[78] Further, low temperature conditions and solvent-
free processing facilitate modification of temperature-sensitive or biodegradable 
materials.[79] 
The immersive nature of the plasma field also enables surface modification of 
surfaces beyond flat 2D substrates. Plasma modification has been used on porous 
substrates for increased cellular infiltration of tissue engineering scaffolds, porous 
biomaterial sterilization, altered wettability of porous polymers, and partial material 
foam membrane removal.[80-83] 
1.4.3 Rationale for plasma modified SMP medical devices 
Although the literature provides a wealth of insight into plasma surface 
modification of polymer substrates, it is sometimes difficult to resolve the multitude of 
differences in process conditions and the operation of custom-built plasma chambers. 
Leveraging the versatility of plasma surface modification approaches also requires 
careful consideration of numerous process conditions including sample fixturing, 
ambient moisture, RF chamber tuning, ionization power, process duration, chamber 
pressure, input gas composition, and process temperature.[84] This dissertation was 
focused on developing regimented, reproducible plasma modifications that are capable 
of being implemented at an industrial scale. To achieve this, all plasma treatments were 
conducted using a commercial-grade plasma treatment system, the Aurora 350 Plasma 
Surface Treatment system by Plasma Technology Systems. This system incorporates 
software for different levels of authorized use and rigorous tracking of all lot conditions. 
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Additionally, the device is housed within a class 100,000 clean room to simulate a 
medical device manufacturing environment. All of these features provide confidence that 
these developed processes could be implemented within a validated device 
manufacturing process. 
Figure 1.4 is an excerpt from the Aurora user manual and provides an overview 
of the type of plasma reactor used in this dissertation. Briefly, a sample is held within a 
vacuum chamber with controlled gasses being introduced at a low pressure (~100 mtorr). 
The gasses flow past the sample in a laminar fashion while radiofrequency (RF) 
electrodes ionize the gas into a reactive cold gas plasma.  
 
 
Figure 1.4: General schematic of the Aurora gas plasma reaction chamber. 
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CHAPTER II 
PLASMA DEPOSITED HYDROCARBON DIFFUSION BARRIERS FOR 
CONTROLLED EXPANSION OF EMBOLIC FOAM DEVICES* 
 
2.1 Introduction 
Plasma deposited hydrocarbon films have been reported for a variety of 
applications, including low friction coatings, dielectric films, optical coatings, and 
surface modifying silica particles for petroleum hydrocarbon removal.[71, 85-87] 
Plasma processes have also been recognized as promising techniques for modifying 
biomaterials, including medical device sterilization, increased cellular affinity, surface 
functionalization, modulated biodegradation of PLLA fibers, and non-fouling 
applications.[29, 66, 67, 77, 80, 82, 88-97] Despite the wide variety of plasma induced 
biomaterial surfaces, a plasma approach has not been proposed to delay the moisture 
plasticization rate of SMP polyurethane foams. 
Low density shape memory polymer (SMP) embolic foams have been proposed 
as a solution to alleviate the drawbacks associated with current embolization 
therapies.[3, 46] Low density SMP foams can be compressed to fractions of their 
expanded volume, allowing them to be delivered through a microcatheter. After 
implantation, a stimulus, such as heat, can restore the low profile foam to its original 
*Parts of this chapter were reprinted from “Characterization of Plasma Deposited 
Hydrocarbon Diffusion Barriers for Embolic Foam Devices,” by Landon Nash, 
Kendal Ezell, Sayyeda Hasan, and Duncan Maitland, 9th IEEE International 
Conference on Nano/Molecular Medicine and Engineering (NANOMED) 2015. 
Copyright (2016) IEEE. 
 18 
 
expanded geometry. Incorporating these low density SMP foams with current embolic 
coiling techniques can significantly reduce the number of coils used to treat an 
intracranial aneurysm, which also reduces procedure time and cost. Similar to other coil 
embolization devices, the embolic foam occludes the aneurysm by disrupting blood flow 
and causing a clot to form within the aneurysm volume. Results reported by Rodriguez 
et al. demonstrate promising biocompatibility for bulk SMP foams implanted in a 
porcine vein pouch aneurysm model.[98] The volumetric expansion capabilities and 
demonstrated biocompatibility of SMP foams make them a promising solution for 
providing more effective embolization and improved healing. However, additional work 
is needed for the effective delivery and actuation of these foams for commercial medical 
applications. 
A major hurdle for the realization of aneurysm filling SMP embolic foams is the 
concept of working time, which is the window of time a physician has to deliver an SMP 
device through a microcatheter, reposition the device in the aneurysm, or retract the 
device before it has expanded sufficiently to bind within the catheter. Bulk material 
modifications have successfully delayed or prevented moisture-plasticized foam 
expansion at body temperature by increasing the material hydrophobicity or rigidity of 
the polymer backbone.[48, 99, 100] However, these bulk modifications simply change 
the linear expansion rate, which requires concessions for ultimate device expansion or a 
working time that is at the clinical minimum of 5 minutes, based on predicate 
devices.[101] Ideally, the foam would actuate in a nonlinear fashion, where the device 
expands a few thousandths of an inch over approximately 10 minutes and subsequently 
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recovers 20–30 thousandths in the next 20 minutes. This idealized expansion profile 
would enable clinically relevant SMP devices for treating neurovascular aneurysms. A 
hydrocarbon surface diffusion barrier deposited using plasma-enhanced chemical vapor 
deposition (PECVD) is proposed to achieve this ideal nonlinear expansion behavior by 
delaying the moisture plasticization rate of the SMP foam without mechanically 
constraining the material.   
 In this study, unsaturated hydrocarbon gasses, including acetylene, ethylene, and 
propylene, are used to deposit aliphatic water diffusion barriers to slow the moisture 
plasticization rate of SMP foams and delay passive foam expansion in vitro. By altering 
the bulk hydrophobicity of the foam and the diffusion characteristics of the surface, the 
actuation profile of the foam can be tailored for delayed expansion in body-temperature 
water. 
2.2 Materials and methods 
2.2.1 Plasma processes 
This study focused on characterizing the functional relationship between process 
parameters and the characteristics of the resulting plasma-deposited film. Process gas 
compositions and room temperature chamber pressures prior to plasma ignition are 
summarized in Table 2.1. Plasma gas compositions were run on silicon wafers at four  
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time intervals between 1 and 30 minutes at the discrete powers of 75, 150, 225, and 300 
Watts for a total 128 different process combinations. 
2.2.2 Sample preparation 
Silicon wafers (University Wafer,Inc.) were cut into rectangles approximately 
1.25 cm x 1.7 cm, cleaned in water and isopropanol under sonication for 15 minutes 
each, dried overnight at 1 torr, and stored under desiccation.  
All SMP polyurethane foams were fabricated according to the protocol reported 
by Singhal et al.[3] with a 33:67 hydroxyl equivalent ratio of triethanolamine (TEA) to 
N,N,N’,N’-tetrakis(2-hydroxypropyl)ethylenediamine (HPED). Foams used for 
differential scanning calorimetry (DSC) were made with an isocyanate composition of 
100 percent hexamethylene diisocyanate (HDI). Two additional foam compositions were 
synthesized for expansion studies using a 50:50 isocyanate ratio of HDI to 
trimethylhexamethylene diisocyanate (TM). Based on results from a concurrent study, 3 
Table 2.1: Plasma gas compositions and flow rates. LE - Low flow ethylene, LEA 
- Low flow ethylene/acetylene, HE - High flow ethylene, HEA - High flow 
ethylene/acetylene, LP - Low flow propylene, LPA - Low flow 
propylene/acetylene, HP - High flow propylene, HPA - High flow 
propylene/acetylene. Process flow rate in standard cubic centimeters (sccm). 
Process 
Label a 
Process Conditions 
Ethylene Flow 
Rate (sccm) 
Propylene Flow 
Rate (sccm) 
Acetylene Flow 
Rate (sccm) 
Average Process 
Pressure (mtorr) 
LE  150 - - 77 
LEA 125 - 25 77 
HE 300 - - 125 
HEA 250 - 50 125 
LP - 150 - 70 
LPA - 125 25 74 
HP - 300 - 119 
HPA - 250 50 119 
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weight percent nanoparticulate tungsten was included in one synthesis, and the other 
included 1 weight percent nanoparticulate aluminum oxide.[102] After synthesis, all 
foams were cut into 1.5 x 1.5 x 4 cm blocks and cleaned in vials using 15-minute 
sonication intervals. The first interval used reverse osmosis filtered water, followed by 2 
intervals of isopropyl alcohol and 4 intervals of reverse osmosis water. The cleaned 
foams were frozen, lyophilized, and stored under desiccation. 
 Cleaned foams were punched into 1 mm diameter, 4 cm long cylinders using a 
biopsy punch and threaded axially over a 150 micron (0.006”) diameter stainless steel 
wire. Foams intended for expansion studies were then transferred to 0.006” diameter 
92/8 Pt/W coils (Motion Dynamics) with a 0.002” diameter propylene suture threaded 
through the lumen. Foam-over-wire (FOW) samples and foam-over-coil (FOC) samples 
were plasma treated while suspended between two 4.5 cm tall glass cuvettes. 100HDI 
FOW samples were used for differential scanning calorimetry. 50TM FOC samples were 
compressed using an SC250 Stent Crimper (Machine Solutions Inc.) after plasma 
treatment. FOC samples were loaded into the crimper at 100°C, equilibrated for 15 
minutes, compressed to an average diameter of 305 microns (0.012”), and held 
compressed during a convective air cooling cycle over a one-hour period. Once at room 
temperature, the samples were removed and stored under desiccation. 
2.2.3 Plasma treatment 
Plasma films were deposited using an Aurora 350 Plasma Surface Treatment 
System (Plasma Technology Systems). The reaction chamber held a single glass shelf 
mounted in the third rack space from the bottom. For mapping the spatial reactivity of 
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the plasma field, silicon wafers were fixed to 4.5 cm tall glass cuvettes placed in a 6 x 6 
grid on the glass shelf. All other experiment samples were fixed to the top of a 4.5 cm 
tall glass cuvette centered in the back third of the shelf. The chamber was evacuated to a 
base pressure of 10 mtorr, followed by process gas introduction into the chamber at the 
specified process flow rate for 1 minute prior to plasma ignition. The plasma field was 
generated using a continuous 13.56 MHz RF power supply, and the process gasses 
continued flowing through the chamber for 1 minute after plasma treatment. The 
chamber was then purged with atmospheric air for 10 minutes and returned to 
atmospheric pressure. All samples were stored in polypropylene bags or trays under 
desiccation. 
2.2.4 Ellipsometry 
Ellipsometric thicknesses were measured using an Alpha-SE Spectroscopic 
Ellipsometer (J.A. Woollam Co.) operating at 380–890 nm and a 70° angle of incidence. 
Data analysis employed a J. A. Woollam optical model assuming a thin transparent film 
on a Silicon substrate. 
2.2.5 Contact angle 
Static water contact angle measurements were made with a CAM 200 
Goniometer (KSV Instruments) using drop volumes of 5 µl. Six contact angles were 
measured for each reported process using a Young/Laplace fitting model. 
2.2.6 X-Ray photoelectron spectroscopy (XPS) 
Silicon wafers were treated with LP and LPA processes at 75, 150, 225, and 300 
watts for X-ray photoelectron spectroscopy (XPS) analysis. Plasma treatment times were 
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chosen to deposit a normalized film thickness of 30 nm for each process. XPS spectra 
were acquired using an Omicron ESCA+ system with a Mg X ray source and CN10 
charge neutralizer. Atomic ratios were calculated using the software Casa XPS. 
2.2.7 Differential scanning calorimetry (DSC) 
Polymer glass transition temperatures (Tg) were determined for 100HDI FOW 
samples using a Q200 DSC (TA Instruments). For dry Tg, a 0.5–2 mg sample was loaded 
into a vented aluminum pan at room temperature, cooled to -40°C, and run through a 
heat/cool/heat cycle from -40°C to 120°C at temperature rates of 10°C/min. Tg was 
determined to be the transition inflection point during the second heat cycle. For wet Tg 
analysis, foam-over-wire samples were immersed in a 50°C water bath for 5 minutes and 
subsequently compressed between laboratory grade Kimwipe sheets (Kimberly-Clark 
Inc.) at 1 metric ton for 30 seconds using a #3925 Hydraulic press (Carver, Inc). The 
foam was then loaded into a vented aluminum pan, cooled to -40°C, and heated to 80°C 
at 10°C/min. Wet Tg was determined to be the heating cycle transition inflection point. 
Wet and Dry Tgs were measured for 5 samples of each reported plasma composition. 
2.2.8 Foam expansion 
Compressed FOC diameters were measured with a stereoscopic microscope 
(Leica KL 2500 LCD). A custom aluminum fixture was used to hold FOC samples in the 
same plane as a 12 mm geometric standard. The fixture was submerged in a 37°C water 
bath and imaged from above at 30 second intervals for 30 minutes. Five diameter 
measurements were taken along the length of each foam sample within the captured 
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images using ImageJ software (National Institutes of Health). Five samples of each 
plasma composition were measured. 
2.3 Results and discussion 
2.3.1 Spatial plasma reactivity 
As seen in Figure 2.1, the plasma deposition rate increases toward the back of the 
plasma chamber, except for a low reactivity margin around the periphery of the shelf. 
This reactivity gradient is in parallel with the flow of process gasses through the 
 
Figure 2.1: Ellipsometry measured spatial deposition map for a 6 x 6 grid of silicon 
wafers raised on glass cuvettes and treated with a low flow ethylene and acetylene 
process at 150 watts for 7.5 minutes. 
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chamber. Thus, the deposition profile increases as gaseous species are exposed to the RF 
field for longer periods of time, increasing their reactivity. To mitigate variations due to 
sample placement within the chamber, all subsequent samples were fixtured within the 
orange region (100–120 nm deposition) shown in Figure 2.1.  
2.3.2 Hydrocarbon film deposition 
 Film deposition profiles were measured to determine the deposition rate for each 
plasma process. The graphs in Figure 2.2 depict typical deposition profiles for high flow 
ethylene (HE) and high flow ethylene/acetylene (HEA) processes. All processes show  
 
linear time dependent deposition profiles. The average R2 value for all 32 linear 
regressions is 0.992. As seen in Figure 2.2, deposition rates increased with increasing 
power, and with the introduction of acetylene (i.e., HEA) at similar process conditions. 
 
Figure 2.2: Plasma film deposition profiles for silicon wafers treated with high 
flow ethylene processes (left) and high flow ethylene/acetylene processes (right) 
as measured by spectroscopic ellipsometry. Error bars are MSE values for the 
optical model fit. 
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 Figure 2.3 summarizes the deposition rates determined from all 128 processes. 
The power-dependent change in deposition rate is assumed to be linear over the studied 
power range, and the average linear R2 value for all 8 plots in Figure 2.3 is 0.960. 
Increasing process power, decreasing process pressure, and introducing acetylene to a 
process all result in an increased deposition rate. In general, ethylene processes have 
faster deposition rates than propylene. 
 
 
2.3.3 Film hydrophobicity 
Static water contact angles for each process gas and power combination are 
summarized in Figure 2.4. Contact angle decreased with increasing process power and 
when introducing acetylene to a process. Propylene processes were consistently more 
 
Figure 2.3: Plasma film deposition rates for ethylene processes (left) and 
propylene processes (right). Deposition rate was assumed to be the slope of the 
linear fit for each time dependent deposition profile for a given process. 
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hydrophobic than ethylene processes, presumably from methyl groups incorporated 
within the film. In general, process parameters that increased film deposition rate tended 
to decrease surface hydrophobicity. All plasma deposited films were significantly more 
hydrophobic than untreated silicon wafers, which had an average contact angle of 37 ± 
1°C. 
 
 
 
 
Figure 2.4: Static water contact angles on treated silicon wafers. Top Panel: 
high flow ethylene (HE), high flow ethylene acetylene (HEA), low flow 
ethylene (LE), and low flow ethylene (LEA) processes. Bottom panel: high 
flow propylene (HP), high flow propylene/acetylene (HPA), low flow 
propylene (LP), and low flow propylene/acetylene (LPA). Untreated silicon 
wafers had contact angles of 37 ± 1° (not shown). Error bars are standard 
deviation (n=6). 
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Selected processes were chosen for XPS analysis to determine the cause of 
power-dependent changes in contact angle. All films were normalized to an average 
thickness of 30.5 ± 1.5 nm. As shown in Figure 2.5, increasing process powers resulted 
in higher rates of film oxidation, which contribute to lower water contact angles. This 
oxidation is likely due to residual radicals from higher energy processes reacting with 
atmospheric oxygen after plasma polymerization. Similarly, the higher reactivity of the 
acetylene processes likely result in higher levels of residual radicals that oxidize after 
plasma treatment. 
 
 
Figure 2.5: Power-dependent film oxygen concentration for low flow propylene 
and low flow propylene/acetylene process films as measured by XPS. 
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2.3.4 Effects on Tg 
Four plasma processes were chosen to encompass a variety of process powers, 
gas compositions, pressures, and ranges of surface hydrophobicity. These processes were 
applied to the 100HDI foams at a normalized thickness of 20 nm. The dry and moisture 
saturated glass transition temperatures for these foams are summarized in Table 2.2.  
 
None of the four processes had a significant effect on the thermal properties of 
dry SMP foams. The glass transitions of moisture saturated SMP foams were marginally 
increased by the diffusion barriers. This suggests that the bulk polymer thermal 
properties are preserved and that any changes in foam expansion rate would largely be 
due to the surface polymerized films modulating the rate of moisture plasticization. 
2.3.5 Effects on expansion rate 
Shape memory polymer foam-over-coil prototype devices are shown in Figure 
2.6. The device dimensions and constituent materials were chosen based on requirements 
for neurovascular delivery such as x-ray contrast and crimped diameter. 
Table 2.2: Glass transition temperatures (n=5) 
Process Label* Contact Angle (Degrees) Dry Tg (°C) Wet Tg (°C) 
Untreated 72.8 ± 0.8 70.0 ± 0.5 14.7 ± 0.7 
LEA75 88 ± 0.5 70.1 ± 0.4 17.1 ± 0.7 
LE225 90 ± 2.5 70.1 ± 0.4 15.6 ± 1.0 
HE300 92 ± 1.3 69.7 ± 0.5 17.1 ± 0.7 
LP75 102 ± 0.6 70.1 ± 0.3 16.8 ± 0.8 
*Label numbers indicate process power 
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Figure 2.7 summarizes in vitro foam expansion for two different plasma 
processes when compared to untreated foams. Working time is assumed to be the 
standard deviation intercept with the dotted line, which represents the lumen of a 
traditional 0.021” microcatheter used to deliver neurovascular coils. 
 The working time for untreated tungsten doped foam is between 2 and 3 minutes 
(Figure 2.7, top image). The ethylene plasma treatment (LEA75) marginally extended 
this working time to between 3 and 4 minutes. Both of these working times are 
unacceptable for the clinical environment. With a working time between 7 and 8 
minutes, the propylene plasma process (LPA75) effectively tripled the working time of 
untreated tungsten doped foam and enabled clinically relevant SMP foam performance. 
 
Figure 2.6: A) Bare 0.006” diameter platinum/tungsten coil. B) Crimped SMP 
foam coating with 0.012” average diameter. C) Expanded 0.040” diameter SMP 
foam coated coil. All scales are 0.1 mm. 
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 When considering alumina doped foams, the working time for untreated foam is 
between 4 and 5 minutes (Figure 2.7, bottom image). Ethylene plasma treatment 
(LEA75) successfully extended working time above the clinical threshold to between 6 
and 7 minutes. Propylene-treated (LPA75) alumina doped foams had the longest 
working times between 9 and 10 minutes. This device performance is well within the 
therapeutic range for safely delivering an embolic coil, including a clinical safety factor. 
 Similar to bulk approaches for delaying SMP foam expansion, the observed 
increases in working time come at the expense of ultimate expanded diameter. 
Maximum expansions were determined after 30 minutes of immersion because it is 
estimated that acute clot formation will limit further expansion on this time scale. 
Untreated tungsten doped foam recovered to an average diameter of 0.044” compared to 
0.037” and 0.027” for LEA75 and LPA75 treated foams, respectively. Control alumina 
doped foam recovered to an average diameter of 0.036” compared to 0.030” and 0.026” 
for LEA75 and LPA75 treated foams, respectively.  
  Although decreases in ultimate expansion limit the potential volumetric 
occlusion for each device, the smallest reported ultimate foam diameter of 0.026” 
provides more volumetric occlusion and surface area through a smaller catheter lumen 
than the largest marketed bare platinum neurovascular coils.[103] This expanded 
diameter also provides similar volumetric filling with a higher surface area when 
compared to 0.027” expanded diameter hydrogel coated HES-14 coils delivered through 
0.019” ID microcatheters.[101] Finally, LEA75 treated alumina foams had comparable 
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ultimate expansion on a similar 5 minute time scale to 0.033” expanded diameter 
hydrogel coated HES-18 coils delivered through 0.021” ID catheters.[101, 104] 
 
 
 
Figure 2.7: Unconstrained expansion profiles for untreated and plasma treated 
SMP foams doped with tungsten (top) and alumina (bottom) nanoparticulates. 
Working time is determined by the standard deviation intercept with the dotted 
line representing a 0.021” lumen microcatheter. 
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2.4 Conclusion 
 This study proved that plasma-deposited hydrocarbon films are effective water 
diffusion barriers for delaying the rate of moisture plasticization in SMP embolic foams. 
Reported device materials, catheter sizes, delivery working times, and expansion 
diameters all fall within clinically relevant device specifications with comparable 
performance to existing neurovascular devices. This benchmark device performance 
study and the favorable biocompatibility of SMP foam make these devices promising for 
future aneurysm therapies. 
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CHAPTER III 
COLD PLASMA RETICULATION OF SHAPE MEMORY EMBOLIC TISSUE 
SCAFFOLDS* 
 
3.1 Introduction 
Shape memory polymer (SMP) foams have shown promise as effective embolic 
materials that address current embolization technique limitations by reducing the number 
of devices needed for treatment and improving long term healing outcomes.[1, 14, 46, 
105] These low density materials can be radially compressed and programmed into a low 
volume configuration to facilitate minimally invasive catheter delivery to a diseased 
vascular anatomy. Once delivered, the material can be stimulated with heat to expand to 
its primary configuration for effective volumetric filling and flow stasis, leading to 
embolization.  These materials demonstrate excellent biocompatibility for aneurysm 
embolization applications, but additional material optimization is necessary to enable 
their use in other applications, such as peripheral embolization devices to treat chronic 
venous insufficiency.[106] 
The implanted SMP foam is intended to serve as a tissue scaffold for thrombus 
formation and subsequent cell-mediated healing. However, gas blown foams inherently 
have membranes between pores, which can limit their performance as tissue 
scaffolds.[3] Namely, implanted foams without interconnected pores can limit cellular 
*Parts of this chapter were reprinted from “Cold Plasama Reticulation of Shape 
Memory Polymer Embolic Foams” Macromolecular Rapid Communications, 2016. 
Copyright (2016) WILEY-VCH Verlag GMBH & Co. 
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infiltration during healing. Low permeability foams can also generate large pressure 
gradients in circulation, leading to potential device failure or migration after deployment 
in peripheral vasculature.  
Reticulation, or the removal of membranes between adjacent foam pores, is 
advantageous for increasing foam permeability to improve material performance. 
Controlled reticulation of SMP foams would provide multiple benefits, such as an 
optimized surface area to volume ratio for intrinsic pathway-triggered blood coagulation 
and flow stagnation within the foam to produce thrombogenic fluid shear rates.[107-109] 
Additionally, reticulated foams would allow for cellular infiltration as the body heals the 
thrombus within the foam.[110]  
Traditional reticulation processes are too aggressive to use with ultra-low density 
SMP foams (~0.015 g cc-1). Commercial techniques, such as acid etching, concussion, 
mechanical cycling, and combustion, can significantly decrease the mechanical integrity 
of the foam. A mechanical reticulation method that utilizes a floating array of weighted 
flexible pins to preferentially puncture foam membranes was previously reported as an 
effective reticulation method for ultra-low density SMP foams with demonstrated utility 
in vessel occlusion.[106] Alternatively, cold gas plasma can be used for SMP foam 
reticulation. The proposed process uses a reactive oxygen (O2) and tetraflouromethane 
(CF4) plasma, commonly used to etch features for microelectronics, to non-thermally 
degrade and volatize high surface area membranes and reticulate SMP foam 
structures.[76, 111-113] 
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Plasma processes have been widely used to alter the surface chemistry of 
biomaterials.[66, 67, 69, 78] Many of these processes increase surface hydrophilicity for 
enhanced cell attachment.[80, 97, 114] Other studies aimed to modify the interior 
surfaces of porous structures.[75, 83, 115] We hypothesize that the proposed plasma 
treatment can be utilized to reticulate foams in a controlled manner. Previously, a group 
used H2O2 plasma to sterilize SMP foams with an observed increase in pore 
interconnectivity.[29] Fu et al. also observed increases in porosity when treating 
polyurethane substrates with an active screen plasma.[81] However, no studies have 
explicitly focused on using plasma to tune the opening of porous structures. This work 
characterizes the effects of cold gas plasma reticulation processes on bulk polyurethane 
SMP films and foams to enhance their functionality and expand their potential use as 
embolic scaffolds. 
3.2 Materials and methods 
3.2.1 Sample preparation 
SMP foams were prepared according to the protocol described by Singhal et al. 
with an isocyanate composition of 100 mol% trimethylhexamethylene diisocyanate 
(TM) and a hydroxyl equivalent mole ratio of 33:67 triethanolamine (TEA) to 
N,N,N’,N’-tetrakis(2-hydroxypropyl)ethylenediamine (HPED).[3] The cured foams 
were cut with a resistive wire cutter into 50 x 50 x 25 mm blocks and washed to remove 
residual surfactants and catalysts. The previously reported cleaning protocol involved 
two, 15-minute sonication intervals in reverse osmosis (RO) water, one interval in a 20 
vol% Contrad® 70 solution in RO water (Decon Laboratories, King of Prussia, PA), and 
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four, 15-minute intervals in RO water.[105] Cleaned samples were frozen in aluminum 
trays and lyophilized for 3 days. Dried foams were stored in polypropylene bags under 
desiccation. 
Neat polymer films were prepared with the same monomer ratios as the foam. 
The monomers were massed into a Flacktek speed mixing cup (Flacktek SpeedMixers, 
Landrum, SC) in a moisture-controlled glovebox. The reaction components were then 
mixed at 3400 rpm for 2 minutes to create a single phase solution. Once mixed, the 
solution was poured into a polypropylene casting tray and oven cured by heating to 
120°C at a rate of 30°C hr-1 and holding at 120°C for one hour. Films were then cooled 
to ambient temperature, milled on a single side to a uniform thickness of 0.2 cm, and 
CO2 laser-cut into 2 cm squares. The top face of the film that was in contact with air 
during curing was preserved for surface analysis. Cured films were stored in 
polypropylene bags under desiccation. 
3.2.2 Plasma reticulation 
Plasma treatment was conducted using an Aurora 350 Plasma Surface Treatment 
System (Plasma Technology Systems). Polymer foam blocks were fixed on a 12.5 cm 
tall aluminum mesh fixture centered in the back third of the reaction chamber. Polymer 
films were fixed to a 4.5 cm tall glass cuvette during treatment. The chamber was 
evacuated to a base pressure of 10 mtorr, and then O2 and CF4 process gasses were 
introduced into the chamber at 200 sccm and 800 sccm, respectively, to bring the 
chamber to a pressure of 385 mtorr. Foam samples were plasma treated at 300 Watts for 
8 or 15 minutes for partial or full reticulation, respectively. Unless otherwise stated, all 
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film samples were treated with the full 15-minute process. Plasma-treated samples were 
stored in polyethylene bags under desiccation. 
3.2.3 Scanning electron microscopy 
Using a resistive wire cutter, foam samples were cut into 1 mm slices parallel 
(axial) and orthogonal (transverse) to the foaming axis. Each slice was mounted to a 
stage with carbon black tape and sputter coated for 90 seconds at 20 mA using a 
Cressington Sputter Coater (Ted Pella, Inc. Redding, CA). Samples were then visualized 
using a Joel NeoScope JCM-5000 Scanning Electron Microscope (SEM) (Nikon 
Instruments, Inc., Melviille, NY). 
3.2.4 Mechanical testing 
Uniaxial tensile tests were conducted at room temperature using an Insight 30 
Material Tester (MTS Systems Corporation, Eden Prairie, MN) with a constant strain 
rate of 50 mm/min. Ultimate tensile strength (kPa), strain at break (%), and elastic 
modulus (kPa) were calculated from the stress-strain curve of each sample. Statistical 
analysis was conducted using a one-way ANOVA with Bonferroni’s multiple 
comparisons test to the untreated control values. 
3.2.5 Permeability 
The porous media properties of the plasma-reticulated and untreated foams were 
measured using a permeability system as previously reported and calculated using the 
Forchheimer-Hazen-Dupuit-Darcy (FHDD) equation (1):  
(1)  −
𝜕𝑃
𝜕𝑥
=
𝜇
𝐾
𝜈0 + 𝜌𝐶𝜈0
2  
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where, ∂P/∂x  is the pressure gradient across the sample in the direction of flow (Pa m-1), 
μ is the dynamic viscosity of the working fluid (Pa s), K is the permeability of the 
sample (m2), ν0 is the Darcy velocity (flow rate divided by the cross-sectional area of the 
sample) (m s-1), ρ is the density of the fluid (kg m-3), and C is the form factor of the 
sample (m-1).[106] Permeability, K, and form factor, C, are geometric parameters of the 
foam. 
Permeability test samples (untreated, partially reticulated, and fully reticulated 
foams) were cut into 16 x 20 mm (OD x length) cylinders using a resistive wire cutter 
and biopsy punch. Each sample was slightly compressed to fit into a 30 x 19 x 16 mm 
(length x OD x ID) poly(methyl methacrylate) (PMMA) tube. UV cure epoxy (Dymax 
See-Cure 1202-M-SC, Dymax Corporation, Torrington, CT) was applied to the exterior 
surface of each cylindrical sample using a plastic spatula. Each sample was then placed 
into the PMMA tube with one end of the cylindrical sample flush with the tube opening. 
The epoxy was UV cured for 30 sec (OmniCure® S1000, Lumen Dynamics, Canada) to 
bond the foam to the tube, and samples were stored under desiccation until testing.  
Prior to permeability testing, each sample was sonicated in water for 1 hr to 
remove air bubbles. The pressure drop across each foam sample was measured for at 
least 30 seconds at flow rates ranging from 0 to 750 mL min-1 (0 to 0.065 m s-1 Darcy 
velocity) to determine the K and C values of the foam. Each sample was initially 
measured with two digital 206,800 Pa pressure gauges (model #DPGWB-06, Dwyer 
Instruments, Michigan City, IN) to determine the peak pressure at maximum flow rate 
and to select the highest resolution transducer for subsequent tests. Based on these 
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results, untreated and partially reticulated samples were analyzed using two 206,800 Pa 
absolute membrane pressure transducers (model #PX42G7-030GV, Omega Engineering, 
Inc.). Fully reticulated samples were analyzed using 2,482 Pa (model #PX409-
10WDWUV, Omega Eningineering, Inc) and 17,240 Pa (model #PX409-2.5DWUV, 
Omega Engineering, Inc.) differential pressure transducers. 
A second-order least squares fit was applied to the pressure gradient versus 
Darcy velocity data to calculate K and C for each sample using Equation 1 with water at 
room temperature as the working fluid. 
3.2.6 Volumetric expansion 
Three cylindrical samples measuring 6 x 5 mm (OD x length) were prepared for 
each reticulation condition using a biopsy punch and razor blade. The foam samples 
were threaded axially onto a 200 micron diameter nitinol wire (NDC, Fremont, CA) and 
loaded into a SC150 Stent Crimper (Machine Solutions, Flagstaff, AZ) preheated to 
100°C. The samples were equilibrated for 15 min before being radially compressed. The 
samples remained constrained until they were cooled back to room temperature. 
Crimped foam over wire samples were stored under desiccation for a minimum of 24 
hours before expansion testing. Samples were mounted within a custom aluminum 
fixture that held the samples in the same imaging plane as a 12 mm measuring reference. 
The fixture was submerged in a 37°C water bath and imaged at 1 minute intervals for 15 
minutes. Five diameter measurements were made along the length of each sample at 
each time point using ImageJ analysis software (National Institute of Health, MD, USA). 
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3.2.7 Static water contact angle 
Static water contact angle measurements were made on untreated and plasma 
treated films (300 Watts for 15 minutes) using a CAM 200 Goniometer (KSV 
Instruments) and drop volumes of 5 µl. Contact angles were measured at day 0, 7, 14, 
21, and 28 post reticulation to examine hydrophobic relaxation of the sample. Three 
contact angles were measured using a Young/Laplace fitting model on 4 separate films 
for a total of 12 measurements for each process and time point. 
3.2.8 XPS 
Untreated polymer films and films exposed to the full plasma reticulation process 
were prepared for XPS analysis. Plasma treated films were analyzed within 3 hours of 
plasma treatment. Single scan XPS spectra were acquired using an Omicron ESCA+ 
system with a Mg X ray source at 150 Watts and a CN10 charge neutralizer. Atomic 
ratios and C1s deconvolution calculations were calculated using Casa XPS software. 
Deconvolution caclulations were made using a Marquardt fitting model. 
3.2.9 Platelet attachment 
Bovine blood was acquired from a slaughterhouse immediately following animal 
sacrifice. To prevent coagulation, the blood was citrated in a 1 L glass jar with a 9:1 
volume ratio of blood to 3.2% sodium citrate solution in phosphate buffered saline (PBS, 
pH 7.4). All blood studies were completed within 8 hours of animal sacrifice. 
Plasma treated (1 and 28 days post-treatment) and untreated films were rinsed 
three times with PBS and placed in a petri dish with the plasma-treated surface face up. 
The samples were submerged in citrated whole bovine blood and incubated for 1 hour at 
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37°C. After removing blood from the petri dish, the samples were rinsed three times 
with PBS and fixed with 3.7% glutaraldehyde at 37°C for two hours. A total of 16 
images were captured for each sample surface condition using a brightfield microscope 
(Nikon Eclipse TE2000-S) at 40X magnification. Platelets were manually counted 
within each field of view, and platelet attachment density was calculated using known 
objective scaling. 
3.2.10 Fibrinogen adsorption 
The wells of a black 96 well plate were blocked with 5% bovine serum albumin 
overnight at 4°C. Wells were washed 3 times with phosphate buffered saline (PBS), and 
laser-cut samples (non-treated control, 0, 7, 14, 21, and 28 day aged plasma-treated) 
were placed into wells with the treated side face up (n=6). A solution of 1 mg/ml human 
plasma fibrinogen (Fg) and 0.2 mg/ml Alexafluor 488 Fg conjugate in PBS was added to 
3 specimens of each sample type (100 µl). PBS was added to the remaining 3 specimens 
per sample type. Samples were incubated at 37°C for 2 hr. The Fg solution was 
removed, and sample surfaces were washed 3 times with PBS. A standard was prepared 
using a serial dilution of the Fg solution in PBS (1.2 to 0.1875 mg Fg/ml and 0 mg 
Fg/ml, n=3), and 100 µl of PBS was added to each sample well. Fluorescence intensity 
was measured (495/519 nm) using a plate reader. A standard curve was prepared from 
the Fg standard and used to quantify the amount of adsorbed Fg on each sample surface. 
3.2.11 AFM 
Plasma-induced changes on polymer topography were assessed using a Bruker 
Dimension Icon AFM in tapping mode. Untreated films and films exposed to the full 
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plasma reticulation process were imaged at 1 hz with 512 lines per image. Amplitude 
error images, 3D surface projections, and calculated changes in surface roughness were 
produced using Nanoscope Analysis software.  
3.2.12 Cell spreading 
Cell-material interactions were evaluated on plasma-treated (0 and 28 days post 
treatment) and untreated films. Films (n = 3 per treatment condition) were sterilized 
under UV light for three hours prior to seeding green fluorescent protein (GFP)-
expressing 3T3 fibroblasts (NIH3T3/GFP, Cell Biolabs Inc., USA) on their surfaces at 
200 cells mm-2. At set time points (3 hr, 1, 3, and 7 days), cells were imaged using 
fluorescent microscopy (excitation: 488 nm, Nikon FN1 Upright Microscope, NY, 
USA). Cell area was quantified using ImageJ software over three images for each film 
condition with five representative cells measured per image. Cell proliferation was 
quantified over three images for each film condition using particle analysis in ImageJ 
with manual verification. Statistical analysis was conducted for the cell spreading and 
cell density data sets using two-way ANOVA with Bonferroni’s multiple comparisons 
test. 
3.3 Results and discussion 
3.3.1 Influence of foam morphology on fluid permeability 
The plasma-induced changes in foam morphology are clearly visualized via SEM 
imaging, Figure 3.1. Untreated foams have inter-pore membranes that are still largely 
intact. The partially reticulated foams have moderate membrane degradation with 
pinholes in the majority of the membranes, providing a degree of pore interconnectivity 
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while maintaining a large surface area of membranes for blood-material interactions. 
Only a small percentage of membranes remain in the fully reticulated foams, while the 
foam struts remain intact. Full reticulation provides an open porous matrix for improved 
fluid permeability and cellular infiltration. 
 
 
Figure 3.1: SEM images of untreated, partially reticulated (8 min treatment), 
and fully reticulated (15 min treatment) foams; scale bar is 1 mm. 
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Figure 3.2 quantifies the increases in material permeability due to plasma 
reticulation. For each reticulation condition, the permeability data is differentiated based 
on ramping the fluid velocity up or down to account for hysteresis. Untreated, partially 
reticulated, and fully reticulated foams had average form factor values of 2.91x105 m-1, 
1.43x105 m-1, and 0.15x105 m-1, respectively. Average permeability values for untreated, 
partially reticulated, and fully reticulated foams were 0.16x10-9 m2, 1.44x10-9 m2, and 
2.55x10-9 m2, respectively. Pressure drops across fully reticulated foams are over 16 
times lower than those of untreated foams at Darcy velocities (5-7 cm s-1) that correlate 
to those typically found in the saphenous vein (7 ± 2 cm s-1).[27] Partially reticulated 
 
Figure 3.2: Pressure differential measurements across plasma reticulated and 
untreated foams with increasing and decreasing fluid flow rates; n = 5, mean ± 
standard deviation. 
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foam permeability fell between that of untreated and fully reticulated foams, consistent 
with the degree of observed membrane removal. The pressure gradient standard 
deviations for partially reticulated foams were significantly higher than those of 
untreated or fully reticulated foams due to the relative inhomogeneity of the reticulation. 
3.3.2 Mechanical testing 
Table 3.1 summarizes the tensile mechanical properties of plasma reticulated 
SMP foams. Increasing reticulation resulted in slight decreases in ultimate tensile stress 
with full reticulation causing the only statistically significant difference when compared 
to untreated foam (p < 0.001).  Strain to failure slightly increased with reticulation, but 
“2 Partial” was the only reticulation condition determined to be statistically different 
from the untreated control (p < 0.05). Ultimate stress and strain to failure are largely 
preserved because the foam struts that are left intact after reticulation contribute more to 
the tensile integrity and overall cross sectional area of the foam when compared to 
membranes. 
Significant decreases in elastic modulus were observed for each reticulation 
condition (p < 0.001). Membrane removal decouples the mechanical link between 
adjacent foam struts. This affords greater flexibility for each strut and results in an 
overall decrease in material stiffness. Comparable decreases in elastic modulus were also 
observed in mechanically reticulated SMP foams.[106] 
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Table 3.3: Tensile mechanical properties of untreated and plasma reticulated foams 
(n=5, average ± standard deviation, One-way ANOVA with Bonferroni’s multiple 
comparisons test to untreated control; *p < 0.05, ***p < 0.001). 
Plasma Duration 
[min] 
Ultimate Stress 
[kPa] 
Strain at Break 
[%] 
Elastic Modulus 
[kPa] 
0 (Untreated) 106 ± 7 38 ± 6 490 ± 86 
1 (Partial) 97 ± 14 42 ± 3 294 ± 62*** 
2 (Partial) 92 ± 6 46 ± 3* 241 ± 32*** 
3 (Full) 79 ± 3*** 44 ± 4 202 ± 18*** 
 
3.3.3 In-vitro shape recovery 
As seen in Figure 3.3, unreticulated foam samples had slow expansion rates at 
37°C with only 2 mm of expansion after 15 minutes of immersion. By comparison, 
 
Figure 3.3: A – Unconstrained expansion measurements of plasma reticulated 
and untreated foam cylinders submerged in 37°C water; n = 15, mean ± 
standard deviation. B – Still frame images of foams at 7 minutes of immersion. 
Scale bars are 5 mm. 
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partially reticulated foams expanded to almost 5 mm in diameter within 15 minutes. 
Fully reticulated samples achieved full shape recovery (6 mm diameter) in as little as 7 
minutes.  
These differences in expansion kinetics can be largely attributed to effects on 
moisture diffusion and moisture-plasticized glass transition temperature (Tg) depression.  
Actuation of SMP foams via plasticization is a known mechanism.[100, 116] Increased 
permeability from membrane removal and increased surface hydrophilicity result in 
faster moisture diffusion throughout the material and a more rapid decrease in Tg, 
increasing the expansion rate at isothermal body conditions. These changes must be 
considered during device development to prevent premature foam expansion and 
excessive device friction within the delivery catheter. 
3.3.4 Time-dependent surface hydrophobicity and thrombogenicity 
Contact angle measurements were made on plasma treated films to confirm the 
hypothesis that increased surface hydrophilicity was a driver for increased expansion 
rates, Figure 3.4. On the day of plasma treatment, films were more hydrophilic with a 
contact angle of 45 ± 3° compared to untreated films with a contact angle of 96 ± 2°. 
However, the plasma treated surfaces exhibited hydrophobic recovery with an increased 
contact angle of 75 ± 4° after four weeks of storage in desiccated air. This partial 
hydrophobic recovery has been previously reported in polar plasma treatment of 
polyurethane substrates, and is attributed to surface polar group rearrangement.[92]  
Platelet attachment provides an indication of material thrombogenicity. As seen 
in Figure 3.4, platelet attachment correlated with increased surface hydrophobicity, with 
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higher platelet attachment to 4 week aged films than to freshly plasma treated films. This 
result suggests that plasma treated devices intended for embolic applications should be 
aged prior to delivery to maximize their thrombogenicity. 
 
 
 
3.3.5 XPS 
XPS was used to characterize changes in plasma induced changes in surface 
oxidation. This technique has higher surface specificity compared to other spectroscopic 
techniques, such as ATR FTIR, that could not differentiate surface chemistry from the 
underlying bulk material. As seen in Figure 3.5, changes in surface oxidation could be 
quantified for untreated 100TMH60 films and films analyzed within 
 
Figure 3.4: Water contact angles (n = 12, mean ± standard deviation) and 
platelet attachment quantification (n = 16 images, mean ± standard error) on 
SMP films 0 and 28 days post plasma treatment compared with untreated films. 
 50 
 
 
 
Figure 3.5: Top – C1s deconvolution spectra for an untreated SMP film. 
Percentages under each curve correspond to the component percentage of the 
total calculated carbon content. Bottom – C1s deconvolution spectra with carbon 
component percentages for an SMP film reticulated the same day as analysis. 
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3 hours of full plasma reticulation treatment. The deconvoluted day 0 spectra had 
significantly higher carbonyl carbon (C=O) content at 37% when compared to the 
untreated control with 7% C=O content. This data supports the hypothesis of decreased 
surface hydrophobicity due to increased surface oxidation. 
Atomic ratio calculations in Table 3.2 also support conclusion for plasma 
induced surface oxidation with surface oxygen content increasing from 63.4% to 77.5%. 
This XPS analysis also revealed a percentage of Fluorine covalently bound to the 
polymer surface after CF4 plasma exposure. Although fluorine peaks could be resolved, 
there was no discernable C1s peak at 292 or 294 eV related to CF2 or CF3, respectively. 
The increase in nitrogen content is attributed to plasma induced cleaning of the material 
surface. This cleaning is hypothesized to reduce the adventitious carbon layer that 
partially convolutes the nitrogen content in the untreated material spectra.[117] 
 
Table 3.2: XPS atomic ratios for untreated and plasma reticulated polymer films 
 C 1s % N 1s % O 1s % F 1s % 
Untreated 77.5 9.6 12.9 0 
Plasma Day 0 63.4 13.4 21.5 1.7 
 
3.3.6 Fibrinogen adsorption 
Similar to platelet adhesion, fibrinogen adsorption to the polymer surface 
provides an indication for material thrombogenicity. Figure 3.6 shows comparable trends 
when compared to platelet adhesion behavior, with an initial decrease in fibrinogen 
adsorption at day 0 and a linear increase with increased surface aging after plasma 
treatment. Initial decreases in surface thrombogenicity and contact activation of the 
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clotting cascade have been previously reported with polar plasmas.[96, 118] However, 
the time dependent effect of plasma reticulation on surface thrombogenicity should be 
carefully considered when plasma reticulating SMP foams for embolic device 
applications. This data suggests that an aging procedure after plasma treatment could be 
important for restoring device thrombogenicity. 
 
 
At 28 days, the amount of adsorbed fibrinogen exceeds the positive control level 
for an untreated SMP films. This result suggests that fibrinogen adsorption could be 
 
Figure 3.6: Effects of plasma reticulated surface aging on fluorescent fibrinogen 
adsorption compared to a PEG hydrogel negative control and untreated SMP 
positive control, n=3. 
Plasma Treated SMP Film
PEG Hydrogel
Untreated SMP Film
Fibrinogen Surface Adsorption
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dependent on other factors, such as surface morphology, in addition to dynamic changes 
in surface chemistry and hydrophobicity.  
3.3.7 AFM 
Quantitative surface morphology images in Figure 3.7 confirm plasma induced 
changes in physical surface structure and roughness. Comparatively large protrusions on 
the untreated surface are shortened on the plasma treated sample due to material 
removal. Although plasma reticulation reduced surface roughness (Ra) from 11.2 nm to 
4.8 nm, the number of nanoscale surface protrusions is significantly increased. These 
features are hypothesized to contribute to the observed fibrinogen adsorption behavior. 
These features could also influence adsorption of other thrombogenic proteins and 
subsequent cellular behavior. 
 
 
 
Figure 3.7: Quantitative 3D projections of untreated (left) and plasma 
reticulated (right) SMP films surfaces with decreased surface roughness.  
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Qualitative amplitude error images in Figure 3.8 further illustrate plasma induced 
changes in surface structure. The protrusions in the lower right panel are hypothesized to 
be urea nanodomains that nucleate during synthesis due to differences in reaction 
kinetics. The surrounding material is hypothesized to preferentially degrade and leave 
these domains that are more resistant to oxidative degradation. Similar domains on this 
size scale have been observed in unpublished TEM images with these materials. 
 
 
 
Figure 3.8: Qualitative amplitude error images for untreated (left) and plasma 
reticulated (right) SMP films with increased nanoscale surface protrusions.  
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3.3.8 Time-dependent cell responses 
 Based on cell spreading morphology, cellular affinity to the plasma treated 
surface is demonstrated in as little as 3 hours after seeding, Figure 3.9A. This initial 
adhesion enables significantly enhanced cell spreading on the plasma treated substrate at 
later time points, as seen after a week in vitro. As indicated by Figure 3.9B, the cells on 
the control film reach a threshold of cell area at ~1 day of culture; however, cells on the 
plasma-treated surface demonstrate highly extended pseudopodia with consistent 
increases in cell spreading over a week of culture. Similar fibroblast spreading behavior 
has been reported for tissue culture polystyrene with a comparable range of surface 
contact angles 63–68°.[119] The observed decrease in cell spreading after 4 weeks post 
reticulation is attributed to the temporal hydrophobic recovery of the surface. The 
increase in cell spreading for both plasma-treated film conditions is hypothesized to be 
partially attributed to the changes in film topography observed using AFM. Previous 
reports have shown significant increases in fibroblast spreading and proliferation for 
surfaces with features down to 13 nm.[120] 
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Figure 3.9: A – Fluorescent images of NIH3T3/GFP fibroblasts cultured on 
SMP films at 0 days and 4 weeks post plasma treatment compared to that on 
untreated SMP films after 3 hours and 1 week of culture. Scale bar is 100 µm. B 
– Quantification of cell spreading over 1 week of culture on SMP films. n = 5 
cells, 3 images per condition for a total of 15 measurements; mean ± standard 
error; Two-way ANOVA with Bonferroni’s multiple comparisons test; *p < 0.05 
relative to untreated control; ***p < 0.001 relative to untreated control. C – 
Quantification of cell density over 1 week of culture on SMP films. 3 images per 
condition; mean ± standard error; ***p < 0.001 relative to untreated control. 
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When compared to the untreated films, both plasma-treated film conditions 
demonstrated higher average cell densities, especially at the later culture time points of 3 
and 7 days, Figure 3.9C. However, only the 3rd culture day “Plasma Day 28” sample 
showed a statistically significant difference (p < 0.001). Temporal changes in surface 
hydrophobicity did not have the same effect on cell proliferation as cell spreading. 
Overall, the apparent surface affinity of the plasma-treated film and interconnected 
porous morphology of the reticulated foam indicate the promise of these materials as 
embolic tissue scaffolds. 
3.4 Conclusions 
This work demonstrates control of bulk SMP embolic foam properties, including 
fluid permeability and volumetric expansion rate, using cold gas plasma reticulation. 
Observed surface effects are transient and demonstrate a tendency to recover toward 
baseline hydrophobicity over the course of several weeks. This surface relaxation has 
significant ramifications for device performance and should be considered in terms of 
specific device applications, packaging conditions, sterilization techniques, and shelf 
life. Overall, plasma treatment increases pore interconnectivity and does not appear to 
impart deleterious effects on cell-material interactions, indicating its utility for 
developing embolic tissue scaffolds. Furthermore, control over the pore interconnectivity 
and surface area to volume ratios of porous materials make this process useful for 
optimizing embolic medical device performance. 
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CHAPTER IV 
CHEMICALLY MODIFIED SHAPE MEMORY POLYMER EMBOLIC FOAMS 
WITH INCREASED X-RAY VISUALIZATION 
 
4.1 Introduction 
The Biomedical Device Lab (BDL) has fabricated ultra-low density SMP foams 
with mass densities as low as 0.015 g cm-3 and high crosslink densities that facilitate 
97% shape recovery. These properties collectively enable 70X foam volumetric 
expansion.[3] Utilization of these low density SMP foams in conjunction with current 
coiling techniques can significantly reduce the number of coils necessary to fill an 
aneurysm to reduce procedure time and cost. Additionally, SMP foam expansion forces 
are significantly lower than those applied by bare platinum coils (BPCs), lowering the 
risk of aneurysm dissection during implantation.[121] Similar to other coil-based 
embolization devices, the embolic foam occludes the aneurysm by disrupting blood flow 
and inducing clot formation within the foam. 
 Many medical applications for SMPs involve endovascular delivery while 
imaging with fluoroscopy. Fluoroscopic device visualization is essential for the proper 
and safe placement of the device into the aneurysm anatomy. In the case of cerebral 
aneurysm embolization, the lack of SMP x-ray contrast can be partially addressed by 
utilizing the SMPs as a coating over a radiodense BPC. Figure 4.1 highlights a limitation 
to this approach. The lefthand frame depicts the typical anatomy of a porcine sidewall 
aneurysm model. The middle frame shows digital subtraction angiography of an 
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aneurysm treated with traditional BPCs, which depicts the dense 2D projection of the 
coil mass that clinicians use as the primary indicator of sufficient coiling. Although the 
aneurysm appears to be densely packed with coils, the average packing density of 
embolic coils ranges between 30-35%.[51] The right hand frame shows an aneurysm 
treated with SMP foam-coated embolic coils.[1] The aneurysm appears to be loosely-
filled according to the radiographic projection, but the limited ingress of injected 
contrast agent proves that the interstitial spaces between the coils are filled with non-x-
ray visible embolic foam and thrombus. Using injected contrast agent as the primary 
indicator of aneurysm embolization is a hurdle for clinical adoption of the device, as it 
deviates from the standard 2D radiographic projection technique. This procedural change 
could potentially lead to over-packing the aneurysm with foam coated coils. The 
proposed x-ray visible SMP formulation is intended to reduce the risk of these 
complications by giving clinicians a better visual for true volumetric occlusion. 
 
Figure 4.1: Left- Untreated porcine sidewall aneurysm model. Middle – Digital 
subtraction angiography of aneurysm model treated with bare platinum coils. 
Ingress of the contrast agent injection is masked by the 2D coil projection. Right 
– Angiography image of aneurysm treated with SMP foam-coated embolic coils. 
Ingress of the contrast injection into the aneurysm is prevented by a mass of 
embolic foam and thrombus. 
 60 
 
 Previously, SMP foam x-ray visibility has been increased through the 
incorporation of tungsten microparticles into the foam matrix.[122] However, this 
approach results in composites with diminished toughness, which raises concerns over 
particulate generation in vivo and subsequent emboli in the blood stream. Furthermore, 
the degree of opacification achieved with microparticle incorporation is not sufficient for 
small-diameter, low density devices, such as those used for neurovascular embolization. 
Radiopaque nanoparticulate additives were investigated to address decreases in material 
toughness by increasing dispersion within the polymer matrix. Low concentrations of 
nanoparticulates improved mechanical strength and toughness, but increasing filler 
concentration to that needed for sufficient x-ray visualization also resulted in diminished 
mechanical properties.[2, 102] Thus, there is a need for improved SMP x-ray contrast 
without sacrificing mechanical integrity. 
 As an alternative to opaque SMP micro or nanocomposites, this work 
incorporates iodine motifs into the polymer matrix to increase x-ray visibility without 
affecting the bulk foam properties. The most typical iodine functional group used in 
biomedical applications is the triiodobenzene ring, which is used in all commercial 
fluoroscopy contrast agents to achieve iodine solution concentrations in the range of 
150–300 milligrams of iodine per milliliter (mg I/ml).[123, 124] Although 
triiodobenzene motifs have been proposed as pendant groups for thermoplastic 
polymers, development of a thermoset biomedical SMP foam system that incorporates 
commercially available contrast agents as monomers is novel.[125] 
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 When compared to particulate additives, the chemical approach of incorporating 
triidobenzene monomers into the material during synthesis was hypothesized to enable 
higher contrast loading percentages without affecting the mechanical integrity of the 
bulk material. This radiodense SMP material system can be utilized to create low density 
foams for embolic applications without the need for metal components such as platinum 
backbones or marker bands. This material system could set the stage for entirely 
polymeric, degradable, embolic devices used for a variety of applications, including 
cerebrovascular or peripheral embolization. While this work focuses on the 
incorporation of iodine into a specific SMP foam system, the information gained here 
could be applied to a range of polymeric biomaterials to enable their imaging during 
implantation. 
 Figure 4.2 shows proof of concept results for combining radiographic contrast 
agents with shape memory polymer foam for x-ray visualization. These 2.5 mm diameter 
foam cylinders were solvent swelled with solutions of iohexol dissolved in ethanol and 
vacuum dried. The expanded foams were imaged through a porcine skull with traditional 
fluoroscopy. These composites showed comparable visualization to a commercial 
GDC10 embolic coil. Although visible, physical incorporation of iohexol produced 
undesirable mechanical properties comparable to a ceramic material, further motivating 
chemical incorporation of triiodobenzene into the polymer backbone. 
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 Figure 4.3 depicts the monomers selected to investigate an x-ray visible SMP 
system. Aliphatic isocyanates were chosen for a polyurethane composition based on 
previous SMP compositions with demonstrated biocompatibility in embolic 
applications.[4, 16] Changing the molar ratio of hexamethylene diisocyanate (HDI) and 
trimethyl hexamethylene diisocyanate was hypothesized to control Tg and bulk material 
hydrophobicity for tailored material expansion rate.[99]  
The proposed contrast agent monomer is 5-amino-2,4,6-triiodoisophthalic acid 
(ATIPA). The x-ray contrast of the ATIPA molecule is derived from the triiodobenzene 
motif, which incorporates three high-z iodine atoms. It is terminated with a primary 
aromatic amine and two carboxylic acids, giving it a functionality of three for 
 
Figure 4.2: 2.5 mm foam devices and a GDC platinum coil imaged through a 
porcine skull. Iohexol was solvent swelled into the foam with ethanol solutions at 
10–40 wt%. 
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crosslinking reactions with isocyanates.  Further, the reaction between isocyanates and 
carboxylic acids yields an amide linkage and carbon dioxide, making ATIPA a chemical 
blowing agent during foam polymerization.[126] 
 Solubility was a significant barrier for the development of this system. ATIPA is 
a hydrophilic solid monomer with negligible solubility in isocyanates. ATIPA is soluble 
in tetrahydrofuran and dimethylsulfoxide, but a solvent-free synthetic procedure is 
preferable to mitigate organic contaminants in end use medical products. The proposed 
polyols 2-butyl-2-ethyl propandiol (BEP), 3-methyl-1,5-pentanediol (MPD), diethylene 
glycol (DEG), triethylene glycol (TEG), 1,2,4-butane triol (BT) and 1,2,6-Hexane triol 
(HT) were selected based on favorable ATIPA solubility and Tg control in the final 
material.  
 
Figure 4.3: Investigated monomers for x-ray visible SMP development.  
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 Figure 4.4 depicts an additional solubility hurdle with these materials. Although 
the premix resins demonstrated favorable solubility, the final material exhibited 
considerable phase separation. ATIPA precipitation was predominantly seen during the 
addition of tertiary amine blowing catalysts. This type of precipitation was also seen 
with early material development with the polyol crosslinking monomers HPED and 
TEA. It was concluded that tertiary amines caused ATIPA to precipitate out of solution 
and should be avoided. Even without traditional polyurethane foaming catalysts, the 
reactivity of ATIPA does not lead to significant adverse effects when foaming the 
material. 
 
 Preliminary proof of concept materials that incorporate DEG and TEG are 
summarized in the accepted publication by Ezell et al in the ASME Journal of Medical 
Devices. However, the focus of this chapter is on the optimization of a system utilizing 
HDI, TMHDI, ATIPA, BEP, MPD, and HT. MPD was proposed to replace TEG and 
 
Figure 4.4: A – Phase separated, cloudy foam with 20 eq% ATIPA synthesized 
with tertiary amine blowing catalyst. B – Optically clear foam with 30 eq% 
ATIPA synthesized without traditional foaming catalysts. 
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DEG to mitigate the risk of degradation product biocompatibility by creating a 
theoretically more biodurable aliphatic system that does not incorporate ether linkages 
that are susceptible to oxidative degradation. 
4.2 Materials and methods 
4.2.1 Foam synthesis 
Table 4.1 summarizes all foam compositions that were synthesized. For the A 
side of the polyurethane synthesis, the reactive hydroxyl, amine, and carboxylic acid 
functional groups are considered for the eq% calculations. A 2% molar excess of 
isocyanate was added to each foam synthesis to account for ambient moisture 
contamination during foam mixing. HDI, TMHDI, BEP, MPD, ATIPA, and HT were 
used as received from VWR Scientific and Sigma Aldrich.  
 Figure 4.5 provides an overview of the ATIPA foaming protocol. In summary, 
hydroxyl (OH) premixes were prepared 1 day prior to foaming by combining a 0.6 
equivalent ratio of non-isocyanate monomers (ATIPA, BEP, MPD, HT) to a 15 ml 
polypropylene flactek mixing cup. The contents were mixed for 30 seconds at 3400 rpm 
in a flactek high speed shear mixer, heated at 50°C for 1 hour, mixed again for 30 
seconds at 3400 rpm, and heated overnight at 50°C. For the 30 and 40 eq% ATIPA 
composition, 5 wt% and 8 wt% anhydrous THF were added to the OH premix to achieve 
complete solubility. 
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Table 4.1: Investigated ATIPA foam compositions. *5 wt% THF addition. **8wt% 
THF addition. 
Foam ID ATIPA% MPD% BEP% HT% NCO Enovate Scale 
1 0.0 ml Eno - 20AT 20 40 20 20 HDI 0 ml 8g 
2 0.5 ml Eno - 20AT 20 40 20 20 HDI 0.5 ml 8g 
3 1.0 ml Eno - 20AT 20 40 20 20 HDI 1.0 ml 8g 
4 1.5 ml Eno - 20AT 20 40 20 20 HDI 1.5 ml 8g 
5 2.0 ml Eno - 20AT 20 40 20 20 HDI 2.0 ml 8g 
6 10HT – 20AT 20 50 20 10 HDI 1.5 ml 8g 
7 20HT – 20AT 20 40 20 20 HDI 1.5 ml 8g 
8 30HT – 20AT 20 30 20 30 HDI 1.5 ml 8g 
9 40HT – 20AT 20 20 20 40 HDI 1.5 ml 8g 
10 0AT – 40HT 0 40 20 40 HDI 1.5 ml 8g 
11 10AT – 30HT 10 40 20 30 HDI 2.0 ml 8g 
12 20AT – 20HT 20 40 20 20 HDI 1.5 ml 8g 
13 30AT – 10HT* 30 40 20 10 HDI 1.0 ml 8g 
14 40AT – 0HT** 40 40 20 0 HDI 1.0 ml 8g 
15 20AT HDI 20 40 20 20 HDI 1.5 ml 8g 
16 20AT 50H/50TM 20 40 20 20 50/50 1.5 ml 8g 
17 20AT TM 20 20 20 20 TMHDI 1.5 ml 8g 
18 25AT 32g 25 40 20 25 HDI 1.5 ml 32g 
19 30AT 32g* 30 40 20 20 HDI 1.5 ml 32g 
Viscous isocyanate (NCO) premixes were prepared in a desiccated glovebox by 
adding 0.4 molar ratio of reactive polyol equivalents to the entirety of diisocyanate 
equivalents in a 150 ml polypropylene flactek mixing cup. Contents were mixed at 3400 
rpm for ten minutes until a single phase was achieved. This premix was shaken at 1 rpm 
at room temperature for 2–5 hours until the mixture achieved a room temperature 
viscosity comparable to honey. For the 0AT composition, 0.04 g of Air Products T131 
gelling catalyst and 0.08 g of Air products BL22 blowing catalyst were added to increase 
the reaction rate during foaming. 
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To stabilize the foam during blowing, 4 wt% DCI990 surfactant was added to the 
NCO premix and mixed for 30 seconds. The OH premix was added to the NCO premix 
and mixed for 30 seconds. 1–2 ml of Enovate was immediately added to the reactive 
resin and mixed for 30 seconds. The reaction was immediately moved to a 90°C oven for 
a 20-minute cure. After curing, the foam skin was removed with a razor, and the foam 
was post cured at 50°C for 12 hours. Post-cured foams were cubed and stored in 
desiccated polypropylene bags. 
 
4.2.2 Physical characterization 
Pore sizes were determined from light microscopy images acquired at 50X and 
100X magnification using a Keyence VHX-5000 metrology system with a variable 
illumination adapter. Foam samples were cut into 2–4 mm slices in the axial and 
transverse planes. Ten pore diameter measurements were taken for each foam image. 
 
Figure 4.5: ATIPA foaming process summary. 
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Six cubes measuring approximately 1 cm3 were taken from each composition for 
density measurement. Density was calculated as the sample mass divided by the product 
of the length, width, and height of the sample. 
4.2.3 Fluoroscopy 
Foam samples were prepared for x-ray imaging by cutting 1cm x 1cm samples 
into 8, 4, 2, and 1 mm thick slices and adhering them to a polypropylene sheet. Each 
foam array included a platinum embolic coil as a radiographic standard. Peripheral 
occlusion prototypes were prepared by cutting foams into 8 mm diameter cylinders and 
axially threading them over a 0.006” stainless steel wire. One prototype was imaged in 
the expanded state while the other was radially crimped using a machine solutions 
SC250 heated stent crimper. The sample was equilibrated at 100°C in the crimping bore 
for 15 minutes, radially compressed, and constrained while cooling to ambient 
temperature. Neurovascular prototypes 2 mm in diameter and without a backbone wire 
were also prepared and radially crimped.  Angiography and fluoroscopy images were 
acquired using a Philips Allura Xper FD20 x-ray system. 
4.2.4 DSC 
Dry Tg was determined using a TA Q200 Differential Scanning Calorimeter on 
5–10 mg foam samples in a vented aluminum pan. The samples were equilibrated at       
-40°C for 5 minutes, then heated to 120°C, cooled to -40°C, and reheated to 120°C at 
temperature ramps of 10°C/min. Tg was calculated as the inflection point of the second 
heating curve.  
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Wet Tg foam samples were immersed in 50°C water for 30 minutes to achieve 
moisture plasticization. Moisture was removed by compressing the foam between tissue 
paper at 2 tons for 30 seconds using a Carver laboratory press. 5–10 mg foam samples 
were added to an aluminum pan and hermetically sealed. Samples were cooled to -40°C, 
equilibrated for 5 minutes, and heated to 100°C at 10°C/min. Wet Tg was calculated 
from the heating curve inflection point. 
4.2.5 DMA 
Dynamic mechanical analysis was conducted using a TA Q800 Dynamic 
Mechanical Analyzer. Foam cylinders were prepared with an 8 mm biopsy punch and 
cut to approximately 5 mm in length using a razor. Samples were equilibrated to 0°C for 
5 minutes and heated to 120°C at 3°C/min while undergoing 40 µm deformation at 1 Hz.  
4.2.6 Unconstrained expansion 
Foams with varying HT content were cut into 2 mm diameter cylinders and 
axially threaded over 0.006” stainless steel wires. Samples were radially compressed 
using a Machine Solutions SC250 heated stent crimper. Crimped samples were allowed 
to relax 24 hrs before being expanded in a 37°C water bath. Samples were imaged at 5-
minute intervals for a total of 45 minutes. Five diameter measurements were taken along 
the length of the expanding foam using ImageJ software. 
4.2.7 ATR FTIR 
ATR FTIR spectra were obtained using a Bruker ALPHA Infrared Spectrometer 
with a diamond ATR crystal. Data analysis was conducted using Bruker OPUS 
Spectroscopy software. 
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4.2.8 Tensile testing 
Dry foam samples were prepared using an ASTM Type IV dog bone punch. 
Uniaxial tensile tests were conducted at room temperature using an MTS Insight 30 
Material Tester with a constant strain rate of 50 mm/min. Ultimate tensile strength (kPa), 
strain at break (%), and elastic modulus (kPa) were calculated from the stress-strain 
curve of each sample. 
4.2.9 Gel fraction 
Foam samples measuring approximately 1 cubic centimeter were cleaned to 
remove residual surfactant using three 30-minute sonication intervals in isopropyl 
alcohol at a 20:1 dilution ratio. The samples were dried under vacuum at 100°C for 12 
hours. Dried foam samples were massed and added to 20 ml vials filled to the shoulder 
with THF and heated at 50°C with 1 Hz oscillation for 48 hours. The THF was removed, 
and samples were dried under vacuum at 70°C for 36 hours. Gel fraction is reported as 
the final sample mass divided by the original sample mass. 
4.3 Results and discussion 
Physical and thermomechanical properties for all foam compositions are 
summarized in Table 4.2. Each foam series is grouped together and named after the 
variable altered in the synthetic procedure. 
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Table 4.2: Physical and thermomechanical ATIPA foam properties. 
  Composition 
Density 
(g/cc) 
Axial Pore 
Size (µm) 
Transverse 
Pore Size 
(µm) Dry Tg (°C) 
Gel Fraction 
(%) 
    n=6 n=10 n=10 n=3 n=5 
1 0.0 ml Eno 0.228±0.011 617±243 574±277 46.8±0.5 - 
2 0.5 ml Eno 0.149±0.013 1039±523 845±370 44±2.3 - 
3 1.0 ml Eno 0.075±0.001 856±321 974±502 47±0.4 - 
4 1.5 ml Eno 0.057±0.001 293±102 306±115 45±1.2 - 
5 2.0 ml Eno 0.045±0.004 401±158 332±126 44±0.7 - 
              
6 10HT – 20AT 0.051±0.001 402±191 311±112 41±1.0 94.5±2.5 
7 20HT – 20AT 0.057±0.001 293±102 306±115 45±1.2 95.1±0.6 
8 30HT – 20AT 0.051±0.001 384±152 364±190 53±2.1 96.9±0.5 
9 40HT – 20AT 0.044±0.001 372±161 434±243 58±2.1 99±0.4 
              
10 0AT – 40HT 0.078±0.003 231±120 233±123 38±0.1 95.8±3.9 
11 10AT – 30HT 0.062±0.009 1360±723 1130±399 37±0.4 98.7±0.7 
12 20AT – 20HT 0.057±0.001 293±102 306±115 45±1.2 95.1±0.6 
13 30AT – 10HT 0.041±0.005 558±346 579±238 52±1.5 96.4±0.6 
              
15 100HDI 0.057±0.001 293±102 306±115 45±1.2 - 
16 50HDI/50TM 0.049±0.002 517±314 482±287 50±0.5 - 
17 100TM 0.049±0.001 552±214 488±274 52±0.5 - 
              
18 
25AT 25HT 
32g 0.040±0.001 515±119 512±249 - - 
19 
30AT 20HT 
32g 0.051±0.005 415±172 320±137 - - 
 
 For compositions 1–5 with varying volumes of Enovate (Eno), there is an 
obvious trend of decreasing material density with increasing volume of physical blowing 
agent. Although there is a statistically significant difference in the dry Tg values (1 way 
ANOVA, α=0.05), this variation is not expected to significantly affect device design 
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criteria. The relationship between material density and pore morphology is better 
illustrated in light microscopy images presented in the next section. 
 Compositions 6–9 with varying hexanetriol (HT) content have comparable 
density and consistent average pore diameters ranging between 300–400 µm. There is a 
statistically significant difference between the dry Tgs for each composition (1 way 
ANOVA, α=0.01). As seen in the gel fraction data, increasing HT content increases the 
material crosslink density. Decreasing the molecular weight between crosslinks leads to 
higher network rigidity and higher glass transition temperatures. These compositions 
demonstrated that HT composition is an effective way to control Tg at fixed contrast 
agent loading (20% ATIPA) and foam density. 
 The ATIPA content was varied for compositions 10–13. HT content was also 
changed to maintain a consistent theoretical crosslink density. These foams 
demonstrated decreased bulk density with increasing ATIPA content. This result is 
expected due to the blowing reaction generated by the two carboxylic acid groups 
present on the ATIPA monomer. Dry Tg increases with increasing ATIPA content. 
Although the theoretical crosslink density for these compositions is constant, the 
aromatic structure of ATIPA is more rigid than the aliphatic HT monomer, increasing 
network rigidity and glass transition temperatures. 
 Compositions 15–17 all have 20 eq% ATIPA with varying isocyanate content. 
Changing the isocyanate composition demonstrated a less significant effect on Tg than 
altered HT content. Although foams with increased TMHDI content were successfully 
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fabricated, they were qualitatively less tough compared to HDI foams and were not 
selected for further device optimization. 
 Average gel fractions for selected compositions ranged between 94.5–99.0%. 
These values are comparable to those reported in previous non-visible SMP foam 
formulations.[3] High gel fractions reduce the risk for complications related to leachable 
chemicals exiting a permanently implanted biomaterial. If necessary, this risk could be 
further mitigated with a more rigorous foam cleaning protocol to remove any potential 
unreacted leachables prior to device implantation. 
 After characterizing foams 1–17, compositions 18 and 19 were fabricated at 4x 
scale for tensile testing and neurovascular prototype fabrication. These compositions 
incorporated chemistry changes to achieve desirable morphology and thermomechanical 
properties. 
4.3.1 Light microscopy 
Figure 4.6 illustrates the impact that increasing blowing agent has on foam 
morphology. The “0 ml” composition that uses no physical blowing agent still has 
porosity due to the ATIPA blowing reaction. Although these pores are comparable in 
size to the 0.5 ml and 1.0 ml foams, the thick strut morphology explains the significant 
difference in bulk material density. Similarly, the smaller pores in the 1.5 ml and 2.0 ml 
foam yield the least dense materials due to thin strut structures. 
Figure 4.7 depicts foams with varying HT composition with comparable pore 
size, density, and strut morphology. It is important to note that composition and 
subsequent thermomechanical properties can be altered independent of foam 
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morphology to enable material optimization toward target medical device applications. 
Using both chemical ATIPA blowing and physical blowing enables morphology control 
independent of composition. 
The foams in Figure 4.8 have significant differences in pore morphology because 
the foaming parameters (premix OH ratio, premix cure time, premix viscosity, etc.) were 
not adequately altered to compensate for changes in ATIPA content. However, this 
series demonstrated miscibility up to 30 eq% ATIPA. It is important to note that the 30 
eq% ATIPA composition required 8 wt% of anhydrous THF during synthesis to prevent 
ATIPA precipitation. 
Figure 4.9 details foams with varying isocyanate content. All foams demonstrate 
qualitative optical clarity. This promising monomer miscibility makes isocyanate 
composition a promising variable to control bulk thermomechanical properties and 
hydrophobicity for tailored material performance. 
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Figure 4.6: Microscopy images at 50X and 100X magnification for an ATIPA foam 
series varying physical blowing agent (Enovate) volume. 
 
 
Figure 4.7: Microscopy images at 50X and 100X magnification for foams with 20 
eq% ATIPA and varying hexanetriol composition. 
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Figure 4.8: Microscopy images at 50X and 100X magnification for foams with 
varying ATIPA content. 
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Figure 4.9: Microscopy images at 50X magnification for ATIPA foam series 
varying isocyanate composition. 
 
4.3.2 Tensile testing 
Figure 4.10 shows representative stress vs strain curves and affiliated 
calculations for a non-visible SMP foam, a 6 volume percent tungsten loaded SMP 
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composite (6 vol% W), a 25 eq% ATIPA foam, and a 30 eq% ATIPA foam 
(compositions 18 and 19).[1, 2, 127] 
 
 ATIPA foam compositions achieve have significantly higher toughness 
compared to previous low density SMP foams. The increased material strength (peak 
stress) is attributed to the aromatic structure of the ATIPA monomer. The BDL 
traditionally avoids aromatic polyurethane monomers, such as Toluene Diisocyanate, 
due to historical concerns with the biocompatibility of aromatic diamines in potential 
 
 
  Peak Stress (kPa) Strain at Break (%) Toughness (kJ/m3) 
SMP Control 109 29 20 
6 vol% W 71 13 5 
25AT 444 86 234 
30AT 350 132 285 
 
Figure 4.10: Top – representative stress-strain curves for x-ray visible foams 
(ATIPA and Tungsten loaded) and a non-visible control foam. Bottom – 
mechanical property calculations from each curve.[1, 2] 
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degradation products.[128, 129] However, aromatic compounds traditionally display 
higher strength when compared to their aliphatic counterparts.[130] Although this 
polymer system was designed to be biodurable with minimal sites for oxidative or 
hydrolytic degradation, the biocompatibility of potential aromatic degradation products 
is worthwhile for future investigation. These investigations should be conducted in 
conjunction with in-vivo vascular implants and in-vitro mass loss studies. 
 Increases in ductility (strain at break) are attributed to a decrease in crosslink 
density compared to the non-visible control SMP foam. The foams traditionally used by 
BDL only use polyols with functionalities of 3 (TEA) or 4 (HPED). These crosslinking 
sites are bridged by short diisocyanate segments (TMHDI or HDI) to create a highly 
crosslinked material. This crosslink density affords excellent shape memory, but at the 
relative expense of overall toughness. This is not a problem in an unloaded foam, but it 
becomes problematic with Tungsten-loaded composites that introduce stress 
concentrations in the strut cross section. Alternatively, the proposed ATIPA 
compositions employ the aliphatic diols MPD and BEP to increase the molecular weight 
between crosslinks for increased ductility. The rigidity of ATIPA enables this chain 
extension while keeping the dry transition temperature of the overall material within a 
functional biomedical range (40–60°C). 
 The combined increases in ductility and strength contribute to significant 
increases in tensile toughness. Compared to non-visible foams, 25AT and 30AT 
compositions are over 11 and 14 times tougher, respectively. Compared to 6 vol% 
Tungsten nanoparticle foams, 25AT and 30AT foams are 46 and 57 times tougher, 
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respectively. This dramatic increase in toughness significantly lowers the risk of 
undesired embolic particles detaching from the foam and flowing downstream from the 
target therapeutic region. However, this toughness can also impact manufacturing. 
Increased difficulty for foam machining and cutting could motivate new device 
prototyping techniques. Additionally, these closed cell foams will need to be reticulated. 
The increased toughness of cell membranes may require significantly different 
reticulation parameters for both mechanical and plasma reticulation. Alternatively, 
foaming parameters could be optimized to introduce cell openers to create open porosity 
in the native foam. 
4.3.3 X-ray imaging 
Figure 4.11 summarizes the x-ray visibility of low density foams with varying 
ATIPA content. The foams with 10–30 eq% ATIPA demonstrate comparable x-ray 
visibility because the blowing ATIPA reaction resulted in lower material density at 
higher contrast agent loading. These opposing trends resulted in comparable iodine 
content within the same expanded sample path length.  
The 8 mm cylindrical peripheral embolization prototypes demonstrated visibility 
in their expanded state, even when imaged through the skull analog. When radially 
crimped, these materials demonstrated visibility comparable to commercially available 
embolic platinum coils. Radial compression also compensates for differences in bulk 
material density, revealing differences in x-ray visualization for samples with varying 
ATIPA content. For example, the radially compressed 30AT sample is noticeably more 
visible than the 20AT sample when imaged through the ½” aluminum skull analog.  
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Figure 4.11: Imaging frame including foam samples with varying ATIPA content at 
varying thickness; platinum embolic coils (GDC10) and catheter segments for 
radiodensity reference; and 8 mm diameter foam cylinder device prototypes in 
expanded and compressed states. Samples were imaged with a camera, unimpeded 
angiography, and angiography through a ½” aluminum human skull analog.  
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Figure 4.12 details foams with a fixed 20 eq% ATIPA composition at varying 
density. Increasing material density results in increased material visualization, with the 
densest foam exhibiting visibility at 1 mm thickness, even through the skull analog. The 
2 mm neurovascular prototypes displayed limited visibility, even when axially crimped.  
 To address the limited material visibility at the neurovascular device scale, future 
prototypes should incorporate foams with higher ATIPA percentages. Alternatively, a 
combinatory approach of chemical opacification and tungsten nanoparticulate loading 
could achieve SMP foam visualization at neurovascular device scales. Based on the 
tensile testing data in the previous section, an ATIPA composite with tungsten 
nanoparticulate stress concentrators is hypothesized to maintain a higher fracture 
toughness than the traditional non-visible SMP foam. This would maintain the existing 
acceptable risk level for undesired embolic particulates, while affording excellent x-ray 
visualization during device implantation. 
 Visualization of the expanded material would be ideal for clinical adoption 
without significant physician training. However, visible crimped devices would also be 
acceptable for device performance. Instead of direct visualization foam expansion, the 
gradual decrease in material visualization would provide a secondary indication of foam 
expansion. 
 83 
 
 
Figure 4.12: Imaging frame including 20 eq% ATIPA foam samples with varying 
densities and thickness; a platinum embolic coil (GDC10) for radiodensity 
reference; and 2 mm diameter foam cylinder device prototypes (20AT, 57 mg/cc) in 
expanded and crimped states. Samples were imaged with a camera, unimpeded 
angiography, and angiography through a ½” aluminum human skull analog. 
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4.3.4 DSC 
Differential scanning calorimetry was used to determine compositional effects on 
Tg and the breadth of thermal transitions. This data is important input for developing 
materials that are tuned to specific device design criteria, including foam expansion rate. 
Figure 4.13 illustrates consistent thermal properties for foams with varying density due 
to physical blowing agent, further supporting the ability to control foam morphology 
independent of transition temperature. Lowering the foam density enables more material 
to crimp to a catheter deliverable cross section. This allows for larger volumetric 
expansion in-vivo and more effective filling to facilitate occlusion. 
 
 
Figure 4.13: Dry DSC thermograms showing minimal change in dry Tg for foams 
with varying density due to changes in physical blowing agent (Enovate) volume. 
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 Figure 4.14 shows incremental control over both dry and moisture plasticized Tg 
based on HT composition. Increasing the molar ratio of the trifunctional HT monomer 
increases the crosslink density to make the polymer structure more rigid and raise the 
glass transition. For each composition, the wet and dry transitions are positioned on 
either side of body temperature (37°C), enabling passive material expansion once 
implanted in the body. Based on these thermograms, the 20HT, 30HT, and 40HT 
compositions were chosen for further analysis toward device development. The 10HT 
composition was determined to have a dry transition too low for sufficient working times 
at the neurovascular device prototype scale. 
Both the transition temperature value and the breadth of transition increase with 
increasing HT content. As seen in the lower left corner of the figure, fully plasticized 
10HT compositions still contained sufficient water content to register water freezing in 
the thermogram.  
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Figure 4.14: DSC thermograms for dry and moisture plasticized 20 eq% ATIPA 
foams with varying HT content.  
 
 
Although less significant, changing the isocyanate content also enabled control 
over Tg. Instead of altering crosslink density, increasing the molar ratio of TMHDI 
increased the rigidity of polymer chains between crosslinks. In addition to increasing Tg, 
higher TMHDI content is also anticipated to increase the bulk hydrophobicity of the 
material to reduce the moisture plasticization rate of the material and overall foam 
expansion time. 
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Figure 4.15: Thermograms for dry and moisture plasticized 20 eq% ATIPA foams 
with varying isocyanate content. 
 
 Thermograms depicting increasing ATIPA composition are illustrated in Figure 
4.15. In addition to increasing Tg, there is also significant increases in transition breadth. 
The transition also becomes much less defined. These changes in the thermogram profile 
motivated further DMA analysis for these select compositions, except for the 40AT 
composition that was too brittle for sufficient analysis or prototyping. 
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Figure 4.16: Thermograms for dry foams with varying eq% of ATIPA. 
 
4.3.5 DMA 
When comparing Figure 4.16 and 4.13, peak Tan δ values are approximately 
20°C higher than DSC dry Tg values. However, the incremental differences in each 
composition are comparable. This DMA data further supports increasing Tg with 
increasing HT content.  
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Tangent δ plots in Figure 4.17 illustrate Tg values 20–30°C higher than dry DSC 
values in Figure 4.15. The DMA curves also shows a similar trend with increasing Tg 
and transition breadth with increasing ATIPA content. Most interesting is the shape of 
the 30AT composition curve. Although a signal peak is evident, the Tan δ signal does 
not return to baseline after the thermal transition. This is indicative of a dampening 
material with a low rubbery modulus, which are both indicative of a poor shape memory 
polymer. It is unclear if this material response is due to the higher ATIPA composition, 
or if the introduction of anhydrous THF altered the reaction kinetics and final structure 
of the polymer system. Based on these results, foam compositions for device prototyping 
were chosen based on the maximum inherent solubility of ATIPA in the other polyol 
 
Figure 4.17: Tangent delta plots from compression DMA of dry 20 eq% ATIPA 
foams with varying HT composition. 
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constituents without solvent. This maximum is in the 20–25 ATIPA eq% range, 
depending on the composition. 
 
 
Figure 4.18: Tangent delta plots for compression DMA of dry foams with varying 
ATIPA composition. 
 
 
4.3.6 Unconstrained expansion 
Foams with varying HT content displayed volumetric recovery behavior in body 
temperature water that is congruent with Tg trends. As seen in Figure 4.18, compositions 
with higher HT content and higher Tg took longer to expand. The 30 and 40 eq% HT 
compositions also showed higher average volumetric recovery (99%) when compared to 
20 eq% HT foams with a lower crosslink density (91%). 
This data shows promise relative to a neurovascular embolization device design. 
With an average crimped diameter of 0.0196” ± 0.001”, these prototypes are close to 
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fitting within a 0.021” microcatheter lumen with a target minimum tolerance of 0.002”.  
Modifications to the blowing agent and surfactant composition can decrease the bulk 
foam density for smaller crimped dimensions, in addition to using a smaller diameter 
device backbone filament. 
These expansion profiles show an estimated minimum working time of 10 
minutes for the 30HT composition and 15 minutes for the 40HT composition. These 
default expansion times are already in the clinically acceptable range without employing 
surface coatings to modulate moisture plasticization.  
 
 
Figure 4.19: Left - Unconstrained expansion profiles of 2mm diameter foams 
compressed over a 0.006” wire and submerged in 37°C water. Right – Snapshots of 
foams after 25 minutes of immersion. 
 
4.3.7 FTIR-ATR 
Infrared spectra in Figure 4.20 do not exhibit significant changes with increasing 
HT content. However, these spectra do show peaks characteristic of polyurethane 
foams.[131-133] The broad peak centered at 3310 cm-1 highlights N-H vibrations. Peaks 
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at 2852 cm-1 and 2923 cm-1 are from symmetric and asymmetric C-H stretching from the 
MPD methyl group. It is worthy to note the lack of an unreacted NCO peak at 2260 cm-1. 
At 1685 cm-1, the C=O urethane peak is significantly right shifted due to hydrogen 
bonding. This is congruent with hydrogen bonded urethane peaks in other polyurethane 
SMP foams with relatively low molecular weights between crosslinks when compared to 
segmented polyurethanes. Strong Amide II and Amide III peaks can be seen at         
1515 cm-1 and 1230 cm-1, respectively. 
 
 
 
 20 eq% ATIPA foam spectra with increasing TMHDI content are shown in 
Figure 4.21. A non-visible 100TM H60 foam is also included for comparison. Increased 
methylation with increasing TMHDI content is evident due to peak broadening between 
2800-3000 cm-1. Compared to the non-visible foam, ATIPA foams do not have a 
 
Figure 4.20: ATR FTIR spectra for 20AT foams with increasing HT content. 
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prominent urea shoulder at 1650 cm-1 due to the lack of H2O chemical blowing used in 
traditional polyurethane foaming. 
 
 
 
 Compositions with increasing ATIPA content, Figure 4.22, show a broadening 
urea shoulder due to higher NH2 reactive groups during synthesis. This differs from the 
urea content present in traditional polyurethane urea foams that use water as a chemical 
blowing agent. 
 
Figure 4.21: ATR FTIR spectra for 20AT foams with increasing TMHDI 
content. Non-visible 100TM H60 control foam spectra included for comparison. 
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4.4 Conclusions 
In this work, chemically modified shape memory polymer foams with inherent x-
ray visualization were successfully fabricated through the incorporation of 
triiodobenzene containing monomers. Altering the molar ratios of the other constituent 
monomers also demonstrated functional changes in these polymer scaffolds that show 
promise for incorporation into embolic medical devices. Future work should pursue 
characterizing the in-vitro cytocompatibility and in-vivo biocompatibility of these 
polymers. 
 
Figure 4.22: ATR FTIR spectra for foams with increasing ATIPA content at 
fixed theoretical crosslink density. 
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CHAPTER V 
CONCLUSIONS 
5.1 Surface modifications 
 The engineered surfaces in this dissertation successfully enabled new shape 
memory medical device performance. Reactive cold plasmas were proven to enable 
independent control over surface and bulk material properties. Decoupling these 
performance criteria can create avenues for biomedical devices that interact more 
favorably with their implanted environment without compromising mechanical integrity 
or shape memory characteristics inherent to the bulk material. The use of plasma 
deposited hydrocarbons for controlled expansion and plasma reticulation for selective 
removal of polymer scaffold membranes are just two examples of a wide array of 
biomedical applications that can be enabled by cold reactive plasmas. 
5.2 Bulk material modifications 
Bulk chemical modification of SMPs to incorporate triiodobenzene monomers 
successfully achieved x-ray visualization with unprecedented performance. A bulk 
approach was necessary to achieve sufficient loading of high atomic weight constituents 
for sufficient visualization. The material system was designed with functional material 
performance and long-term degradation in mind. However, biologic surface interactions 
with this material remain largely uncharacterized. Cytocompatibility and pathology of 
implanted ATIPA foam are critical data-sets that are still necessary for assessing the 
biomedical utility of these materials. Should issues arise during this assessment, new 
plasma surface modifications could be leveraged to solve potential surface problems. 
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5.3 Challenges and future directions 
Although plasma-deposited hydrocarbons have demonstrated utility, their impact 
on biocompatibility still remains unanswered. Alternative solvent-based neat polymer 
coatings were developed in parallel to the plasma-based approach. These neat coatings 
have the same basic composition as the substrate SMP foam and serve as diffusion 
barriers with the added benefit of adhering the SMP foam to other device substrates. 
This neat coating is less sensitive to process and aging conditions and is being 
incorporated into the development of a commercial embolization device. For the time 
being, plasma hydrocarbon films are not being actively incorporated into a translational 
medical device design. 
In contrast, plasma reticulation affords unique properties that cannot be achieved 
with alternative processes. Future work should expand on the control of surface 
topography relative to cell-material interactions, including the inclusion of masking 
techniques for gradient control of cellular behavior within tissue engineering scaffolds. 
The long-term biocompatibility, hydrolytic stability, and oxidative stability of x-
ray visible ATIPA foams remain unanswered within this work. Characterizing these 
material properties with in-vitro degradation experiments and in-vivo implantation will 
be important for facilitating the translation of these materials to the clinic.  
Finally, the closed cell nature of ATIPA foams and mechanical integrity of intact 
membranes make plasma reticulation an attractive option for producing open celled 
scaffolds. However, similar characterization of plasma-reticulated ATIPA surfaces 
should be conducted to identify cytocompatibility, surface composition, and surface 
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topography. Alternatively, cell opening agents could be incorporated to the material 
synthesis to create scaffolds that inherently cure in an open celled configuration. 
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APPENDIX 
EFFECTS OF ELECTRON BEAM STERILIZATION ON SHAPE MEMORY 
POLYURETHANE FOAMS 
A.1 Purpose 
This appendix summarizes results from an engineering study assessing the 
effects of electron beam (E-beam) sterilization on shape memory polymer foam 
compositions used for the PED (Peripheral Embolization Device) currently under 
development by Shape Memory Medical, Inc.   
This experiment was designed to investigate E-beam dose-dependent effects on 
three PED shape memory polymer foam compositions. Changes in thermomechanical 
properties and chemical composition were characterized for foam and neat polymer 
sample geometries. 
A.2 Background 
 The purpose of this study is to provide a quantitative assessment of dose-
dependent PED performance criteria, particularly effects on shape memory polymer 
(SMP) foam expansion rate.  Results from a previous sterilization study on SMP foam 
showed negligible effects on wet glass transition temperature (Tg), dry Tg, mechanical 
properties, device morphology, shape memory capacity, and bulk material chemistry as 
determined by FTIR. These results make E-beam radiation a promising candidate for 
sterilizing shape memory polymer foam, especially when packaged with desiccant in a 
nitrogen-purged, vacuum-sealed foil pouch environment that mitigates oxidative species 
generation from ambient moisture and atmospheric oxygen during sterilization. 
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 The most interesting result from preliminary testing was a trend of increasing 
expansion time with increasing sterilization dose. As shown in Figure A.1, this trend 
appeared to be more pronounced in compositions with lower percentages of N,N,N’,N’-
Tetrakis(2 hydroxypropyl)ethylenediamine (HPED). The hypothesis is that compositions 
with higher percentages of Triethanolamine (TEA) are more susceptible to radiation-
induced material changes. This study will utilize compositions with different ratios of 
TEA and a composition that replaces TEA with glycerol, a polyol that has been shown to 
help resist oxidative degradation. 
 This study is designed to determine the repeatability of these dose- and 
composition-dependent expansion results and to understand their underlying cause. 
Clinically relevant PED foams with varying compositions will be sterilized at varying 
doses and their expansion profiles quantified. Neat polymer films with varying 
compositions will also be sterilized in different packaging environments to quantify the 
effects of material oxidation. 
Preliminary results that motivated this study are summarized in the manuscript 
“Effects of Sterilization on Shape Memory Polyurethane Embolic Foam Devices” 
submitted to the ASME Journal of Medical Devices. A summary of the study process 
flow is outlined in Figure A.1.  
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A.3 Methods 
A.3.1 Sample preparation 
 All samples were prepared in the Controlled Fabrication Laboratory at Texas 
A&M University under work order BG06. 8 mm foam samples were crimped over 
0.008” nitinol wire. Crimped foam samples were placed within stainless steel introducers 
with luer locks (Biotex Part # 015-2513). Neat films were cut into 1.5 cm squares and 
adhered to a 0.020” polyethylene sheet using double-sided tape. All samples were 
packaged in nitrogen-purged, vacuum-sealed foil pouches (Beacon Converters, Biotex 
Part # 015-2000-013) with molecular sieve desiccant (Multisorb MiniPax), except for 
“O2 Films” packaged with ambient air and moisture without desiccant. 
  
 
Figure A.1: Sample process flow. 
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Table A.3: Foam traceability table 
CFL Work Order BG06 
Foam IDs 
H30 160603PEDMH01 
H60 160408PEDMH01 
G40 160225RCHGF05 
 
Table A.2: Neat film monomer traceability table 
Neat Film Monomer Lot #s 
HPED BCBQ0036V 
TEA BCBN8242V 
HDI H0324 
 
A.3.2 Irradiation 
 Samples were irradiated at the Texas A&M National Center for Electron Beam 
Research on July 28, 2016. Dosimetry was measured using Alanine dosimeters and a 
Bruker Alanine dosimeter reader.  
A.3.3 Expansion tests  
 Samples were held in a custom fixture that positioned the samples in the same 
imaging plane as a ¼” measurement reference for image calibration. The fixture was 
immersed in 37°C water and imaged at 30-second intervals until foam expansion was 
observed. Using ImageJ software, five diameter measurements were taken along the 
length of all 3 foam samples at each time point, for a total of 15 measurements. After 
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expansion, ~50 mg of moisture-plasticized foam was kept for wet DSC analysis. The 
remaining foam was vacuum dried at 50°C for ATR and dry DSC analysis. 
A.3.4 Differential scanning calorimetry (DSC)  
 DSC thermograms were obtained using a TA Instruments Q200. Dry Tg cycles 
consisted of hermetically sealing dried foam samples in an aluminum pan and cooling 
the sample to -40°C, holding isothermal for 2 minutes, ramping to 120°C, isothermal 2 
minutes, returning to -40°C, isothermal 2 minutes, and ramping again to 120°C. All 
heating and cooling rates were 10°C/min. Tg was calculated from the inflection point on 
the second heating ramp to 120°C using TA Universal Analysis software. Wet DSC 
cycles consisted of cooling the hermetically sealed wet sample to -40°C, holding 
isothermal for 2 minutes, and ramping to 80°C at 10°C/min. Glass transition was 
determined as the inflection point of the thermogram using TA Universal Analysis 
Software. 
A.3.5 ATR FTIR 
 ATR FTIR spectra were obtained using a Bruker ALPHA Infrared Spectrometer 
with a diamond ATR crystal. Data analysis was conducted using Bruker OPUS 
Spectroscopy software. 
A.4 Results 
A.4.1 Foam dosimetry 
 As seen in Table A.3, the delivered dose for each sample group was consistently 
within 1 kGy of the desired target dose. With the exception of the absolute H30 dose on 
the top of the pouch, all dosimeters were placed on the back of the foil pouch, opposite 
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of the beam source. When comparing the absolute H30 dose to the dose delivered after 
the beam passes through the H30 sample, there is a maximum dose shielding effect of 
only 0.362 kGy. 
Table A.3: Foam sample dosimetry 
 
Target Dose (kGy) 
 
25 kGy 40 kGy 60 kGy 
Absolute (H30) 25.985 40.329 60.487 
H30 25.623 40.311 60.244 
H60 25.842 39.517 59.542 
G40 25.539 40.577 59.659 
 
A.4.2 Foam DSC 
 Table A.4 summarizes the dry and wet glass transition temperatures for each 
composition and dose. As seen in previous studies, there is no significant difference in 
dry Tg with increasing dose. Although there is a slight decrease in wet Tg with increasing 
dose, this is not anticipated to negatively impact medical device performance because all 
untreated foam compositions have wet Tgs significantly below body temperature. 
 The wet Tg for the H30 samples irradiated at 25 and 40 kGy could not be 
determined because the moisture plasticized glass transition temperature was too close to 
the freezing point of water for accurate calorimetric assessment. A glass transition 
temperature close to 0°C for irradiated H30 samples is realistic based on wet Tg 
depression trends in the other compositions. 
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Table A.4: Foam Tg summary 
 Glass Transition Temperature (°C) 
 Control 25 kGy 40 kGy 60 kGy 
H30 Dry 55.99 54.51 54.55 54.16 
H30 Wet 4.85 - - 5.77 
H60 Dry 67.64 66.63 66.52 66.25 
H60 Wet 18.18 15.12 17.32 16.76 
G40 Dry 84.28 83.15 83.29 82.15 
G40 Wet 32.91 29.2 28.31 27.67 
 
A.4.3 Foam expansions 
 Figures A.2 to A.3 depict the unconstrained expansion data for each foam 
composition and dose configuration. In all cases, radiation caused an increase in ultimate 
expansion time. The G40 composition had the most dose-dependent trend in expansion 
time, with increasing dose leading to longer expansion times. The H30 and H60 sample 
groups did not show a dose-dependent trend for expansion time. For all 3 compositions, 
the highest dose of 60 kGy had the smallest variation in expansion profile, as indicated 
by standard deviation. 
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Figure A.2: 37°C aqueous unconstrained expansion of 1 cm long, 8 mm diameter 
H30 foam samples compressed over 0.008” nitinol wire.   
 
 
As shown in Figure A.2 irradiated H30 samples had longer expansion times and 
larger standard deviations when compared to the untreated control foam. This increase in 
expansion time is attributed to increased intermolecular interactions between dangling 
chains at scission sites. Assuming this change in material performance is accounted for 
in the device design, it should not significantly affect the utility of an SMP embolic foam 
device. 
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Figure A.3: 37°C aqueous unconstrained expansion of 1 cm long, 8 mm diameter 
H60 foam samples compressed over 0.008” nitinol wire.  
 
 
 The H60 samples in Figure A.3 shows a more exaggerated increase in expansion 
time than the H30 cohort. Previous studies showed an opposite trend, with lower HPED 
content foams showing a more significant increase in expansion time with increasing 
dose. Regardless of this discrepancy, the observed changes in expansion time for any 
data set have not been significant enough to significantly impact device performance. 
 The 40 kGy curve is truncated due to a failure during image acquisition. These 
samples continued to expand, but there are no images past the 8-minute time point for 
quantitative measurements. Images were captured and measured to convey changes in 
expansion rate, not ultimate shape recovery. The irradiated samples are not plotted to full 
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expansion, but previous results show there is no concern for diminished ultimate shape 
recovery for the dose range of 25–60 kGy. 
 
Figure A.4: 37°C aqueous unconstrained expansion of 1 cm long, 8 mm diameter 
G40 foam samples compressed over 0.008” nitinol wire.  
 
 The G40 foams in Figure A.4 howed the clearest trend for increasing expansion 
time with increasing dose. This plot suggests the G40 composition is not resistant to 
radiation effects as hypothesized in the study rationale. 
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A.4.4 Foam ATR 
 
Figure A.5: ATR FTIR Spectra of SMP foams after expansion and vacuum drying 
at 50°C. A – H30 foam. B – H60 Foam. C – G40 Foam.  
 
 The ATR spectra in Figure A.5 A–C show no significant dose-dependent 
changes in any of the three material compositions. Although slight changes in foam 
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expansion kinetics are observed, the changes in the material are not significant enough to 
change the infrared spectra 
A.4.5 Film dosimetry 
 As with the foam dosimetry, the dose delivered to the neat polymer films was 
within ±3 kGy of the target dose. Film dosimetry is summarized in Table A.5. 
Table A.5: Film dosimetry summary 
 Target Dose 
 25 kGy 40 kGy 60 kGy 
H30 N2 26.496 42.197 62.396 
H60 N2 26.365 40.587 60.543 
H30 O2 26.263 41.472 61.197 
H60 O2 26.677 41.920 61.742 
 
A.4.6 Film ATR 
 Changes in packaging conditions were anticipated to have the greatest effect on 
oxidation reactions that occur predominately at the material surface. ATR was used over 
transmission FTIR to achieve higher resolution of the surface chemistry. Figure A.6 
summarizes ATR spectra of neat polymer films sterilized under inert packaging 
conditions. All spectra were identical, except for a new peak at 960 cm-1 for the H60 
sample sterilized at 40 kGy. This peak corresponds with an aliphatic amine oxide 
functional group.[134] This group is hypothesized to form due to the oxidation of the 
tertiary amine in TEA and HPED. This amine oxide peak was not observed in any of the 
N2 packaged foam ATR spectra. 
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Figure A.6: ATR spectra of neat polymer films irradiated under inert packaging 
conditions (N2). 
 
 Figure A.7 summarizes ATR spectra for neat polymer films sterilized under 
ambient oxygen and moisture. Samples irradiated under these conditions had more 
amine oxide formation compared to the inert packaged materials. Amine oxide peaks at 
960 cm-1 are more pronounced and occur at lower doses. When compared to H30 
material, the H60 composition was more susceptible to amine oxide formation in both 
packaging configurations. This result is congruent with higher H60 sensitivity to 
radiation-induced changes in foam expansion rate. 
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Figure A.7: ATR spectra of neat polymer films under ambient oxygen and moisture 
packaging conditions (O2). 
 
A.4.7 Film contact angle 
 Contact angle measurements were inconclusive. It is hypothesized that the two 
sides of the polymer film have different surface finishes that would affect the wetting 
behavior of a water droplet. The film sides were not documented during sample 
preparation and testing; thus, the contact angle data is convoluted by changes in material 
composition and undocumented differences in surface roughness. The samples have 
since been exposed to ambient moisture for multiple days, further convoluting any 
subsequent tests. This data was intended to support hypotheses in material changes but is 
not critical for assessing device performance. This data was determined to be secondary 
and not critical enough to repeat for this study. 
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A.4.8 Color changes 
 Yellowing was observed for all neat and foamed compositions at all doses. This 
aesthetic change is hypothesized to be independent from amine oxide formation 
observed in select ATR spectra because it is observed in all irradiated samples. This 
color change affects wavelengths in the visible spectrum not covered in FTIR analysis. 
Electron beam–induced color changes are not atypical for materials, even at low doses. 
When considering all other data, these color changes are considered to be cosmetic with 
negligible effects on material performance. Observed color changes are summarized in 
Figures A.8 and A.9. 
 
 
Figure A.8: Qualitative color change of neat polymer films. Film thickness reported 
for each film in mm. 
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Figure A.9: Qualitative color change of crimped polymer foams. 
 
A.5 Conclusion 
Based on the presented body of data, the proposed material compositions have 
stable performance characteristics when exposed to 25–60 kGy of Electron beam 
radiation under inert packaging conditions. Packaging under inert conditions helps 
prevent the formation of amine oxides, especially at lower doses, such as 25 kGy. 
Medical devices using these material compositions are anticipated to maintain important 
performance behavior, including shape memory expansion, when sterilized at an Ebeam 
dose of 25 kGy.  
 
